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AIM AND OBJECTIVES 
 
 
AIM: 
To compare the efficacy of Parangisakkai Chooranam” (Internal) and Karappan 
Ennai (External) with and without Yogam in  Karappan. 
  
OBJECTIVE:   
❖ To study the Siddha basic principles, Envagai Thaervu  in the patients of Karappan . 
❖ To study the effectiveness of Yogam in the management of Karappan along with trial 
drug. 
❖ To perform Biochemical analysis of the trial drug. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
SIDDHA ASPECT
 
❖ 
❖ 
FUehb E}y; 
‘tay;jdpNy g+ehf kz;izj; jhNd 
tUe;jpaJ Gj;Jg;Nghy tj;ijahFk; 
gay;nkhopaPu; Njfj;jpy; fpUkpjhNd 
gue;Jufp Fl;lk;Nghy; Gs;spfhZk; 
            kayJTq; fpUkpAe;jhd; ele;JGf;fpy;  
NkdpaJ rurnud ntbj;Jg; Gz;zhk; 
fay;ngUFk; Foy;kltPu; nrhy;yf; Nfspu; 
   fufuj;Jr; nrhwpngUFq; fughd; jhNd’ 
  ‘rq;ifapy; tplfug;ghd; tUkhNwJ 
   rhuKld; fpUkptpOe; jd;ikNaJ 
  cl;bzNk mjpfk;tU kpe;jpupa Nghfj;jh 
   YDUfp aj;jpNy NtTnfhz;L 
  el;lzkha; nte;jnjhU kr;irjd;dpy; 
   ehl;lkpl;Nl fpUkpaJ aZFk; NghJ 
  kl;LlNd fpUkpnay;yhk; gwe;jq;Nfwp 
   tifAlNd khq;fp\j;ijj; Jisj;JNkTk; 
  jpl;lKld; tplfug;ghd; gwe;JNkNy 
   jpdTlNd guguj;Jr; nrhwpAz;lhNk’ 
                            -   FUehb E}y;  
guuhr Nrfu fpue;jp epjhdk;: 
            thjgpj;jq; fgkpit %d;Wte; 
   NjJtha;nt apyhd; kbahypfw; 
  Nfhijahu;kayhu; ntau; thw;Fspu; 
   NgjePupit khYs NgRNfspd; 
  Ntjf; fhw;wpjp ew;gid nty;yj;jhy; 
   ghfkpd;fs; thd;Nkjpg; ghnda;apy; 
  jhfkhypd; tLf;fdp rhu;jyhy; 
   Nkhfthio tOjiy Ks;spf;fha; 
  fhAk; gy;yplj; jhw;Ruj; jhw;fdy; 
   VAk; tz;nlyp ahy;tUNkJ ntd; 
  UA ey;ywp thd uUspdhu; 
   kha khd fug;ghd; tiffNs’ 
- guuhr Nrfu fpue;jp epjhdk;  
Classification of eczema in siddha aspect: 
 In siddha aspect, there are 7 types of karappan in text. They are 
1) Vaatha karappan 
2) Kanda karappan 
3) Varachi karappan 
4) Thimirvatha karappan 
5) Kabala karappan 
6) Pitha karappan 
7) Sethuma karappan 
Theerum karappan, 
1) Vatha karappan 
2) Pitha karappan 
3) Varachi karappan 
4) Kabala karappan 
As per ‘Yugi Vaidhya Chindamani - 800’ the types of  Karappan are seven: 
1. Vatha karappan 
2. Kanda karappan 
3. Varatchi karappan 
4. Thimirvatha karappan 
5. Kabala karappan 
6. Azhal karappan 
7. Iyya karappan.  
In “Pathinen Siddhar Balavagada Thirattu”, Karappan is classified into18 types: 
1. Vali karappan,  
2. Azhal karappan,  
3. Iyya karappan,  
4. Ari karappan,  
5. Oothu karappan,  
6. Soolai karappan,  
7. Vedi karappan,  
8. Mandai karappan,  
9. Pori karappan,  
10. Sattaik karappan,  
11. Odu karappan,  
12. Karun karappan,  
13. Sen karappan,  
14. Kolli karappan,  
15. Thoda karappan,  
16. Vaalai karappan,  
17. Varal karappan,  
18. Veengku karappan.  
In the text ‘AthmaRakshamirtham’ the classification of Karappan is of 20 types: 
1. Vali karappan, 
2. Azhal karappan, 
3. Iyya karappan, 
4. Karun karappan, 
5. Sen karappan, 
6. Mandai karappan, 
7. Ari karappan, 
8. Pori karappan, 
9. Kiranthisoolai karappan, 
10. Vaalai karappan, 
11. Othu karappan, 
12. Sevvappu karappan, 
13. Kolli karappan, 
14. Kadi karappan, 
15. Vengu karappan, 
16. Uthir karappan, 
17. Sattai karappan, 
18. Vedi karappan, 
19. Singamuga karappan, 
20. Eri arappan 
CLINICAL FEATURES OF KARAPPAN  
  “vd;gJ fug;ghd; jd;idapak;gpL khWNfspu; 
      ed;gpLk; thjk; gpj;jk; eyq;nfl;Lj; jhDk; tPq;Fk; 
 Gz;gLq; fuq;fs; re;JGiye;Jly; fLj;JNehFk; 
      td;Gld; ntbj;Jr; #iytUtJ uzkPnjd;Nd” 
cisQ;Rnky apjvd;rPjq; fhZk; 
  cskha; %j;jpue;jhY Uq;fptpOk; 
misQ;RNk aq;fnky;yhQ; nrhwpAz;lhFk; 
moyhf ntJk;gyhf; iffhNyhAk; 
GisQ;R Nkypq;fj;jpw; Ad;NghypUj;jpg; 
nghbnghbaha; Rz;zhk;Gf;fw; Nghy;tpOk” 
- mfj;jpau; ,uz E}y; 
According  to  Agathiar  Rana Nool  clinical features about  Karappan: 
• Classified into 80 types 
• Produced due to derangement of Uyirthathu(vital humors), Vaatham, Pitham and 
Kabam 
• Symptomised by  
➢ Itching 
➢ Cracking 
➢ Oozing 
➢ Pus exudation 
➢ Sloughing 
➢ Oliguria 
➢ Fatigue 
NAADI : 
 
The above mentioned nadi can cause karappan as per sathaga naadi. 
DIAGNOSIS OF KARAPPAN:  
Diagnosis of Karappan in Siddha system is mainly based on Envagai Thervu (Eight 
ways of examination) and also on other factors like, 
• Uyir Thaathukkal (vital humors) 
• Udal Thaathukkal (body constituents) 
• Gnanenthiriyam (organs of perception) 
• Kanmenthiriyam (Motor organs) 
UYIR THATHUKKAL 
Vaatham 
• In Karappan commonly affected types of Vaatham are Abanan, Viyaanan, 
Samaanan and Devathathan. 
• Derangement of Viyanan leads to itching, dryness of skin, thickness. 
• Involvement of Samanan leads to imbalance of functions of other Vaayukkal. 
• Derangement of Devathathan leads to sleep disturbances. 
• Derangment of  Abaanan leads to constipation. 
In Pitham 
• Karappan commonly affected type of Pitham is Ullollithee (Prasakapitham). 
• Normally Prasakapitham gives complexion to the skin. In Karappan the skin 
becomes hyperpigmented and lose its normal colour. 
Kabam 
• Kabam is usually not affected in karappan. 
 UDAL THAATHUKKAL 
Imboothangal are important in the formation of body constituents mainly by Pancha 
bootha panchikaranam theory. Derangement of body constituents especially Saaram and 
Senneer causes karappan. 
Derangement of Saaram leads to depression and tiredness of mind and body. Deranged 
Senneer causes itching, affects colour of the skin. 
 
GNANENTHIRIYAM 
Imboothangal forming the basic constituents of Gnanenthiriyam get deranged. 
Commonly affected Gnanenthiriyam is Mei producing itching, papule, vesicle formation, 
oozing, crusting, scaling, and hyperpigmentation. 
KANMENTHIRIYAM 
Imboothams forming the basic constituents of Kanmenthiriyam were not commonly 
affected in karappan. 
PINIYARI MURAIMAI (DIAGNOSTIC METHODS) 
Piniyarimuraimai is the method of diagnosing disease. It is based on the following 
principles: 
1. Poriyalarithal (Examination by the sense organs) 
2. Pulanalarithal (Examination of the sensory function) 
3. Vinaathal (Interrogation) 
 Poriyalarithal and pulanalarithal goes hand in hand with the concept of examining the 
patient’s ‘Pori’ and ‘Pulan’ with that of physician’s ‘Pori’ and ‘Pulan’. 
‘Vinaathal’ is a method of enquiring about the details of the patient’s problem from his 
own words or from the person who take care of the patient, when the patient is not able to speak 
(or) if the patient is a child.’ 
Envagai Thervu (Eight Types of Examination) 
 ‘ehbg; guprk; eh epwk; nkhoptpop 
             kyk; %j;jpu kpitkUj;Jt uhAjk;” 
                                                -  Njud; 
The Eight ways of Examination 
1. Naadi (Pulse reading)  
2. Sparisam (Tactile sensation)  
3. Naa (Tongue)  
4. Niram (Color)  
5. Mozhi (Speech or Voice)  
6. Vizhi (Eyes)  
7. Malam (Stools)  
8. Moothiram (Urine)  
1.Naadi 
In Karappan the following types of naadi could be felt. They were, 
▪ Vathapitham 
▪ Pithavatham 
2.Sparisam 
In Karappan patient’s general body temperature  -  slight warmth, dryness, roughness 
and elevation of skin was noted. 
3.Naa 
In some patients, coated tongue was noted. 
4.Niram 
            Skin colour becomes hyper or hypopigmented in the affected area. 
5.Mozhi 
            No change or disturbance in voice was noted. 
6. Vizhi 
           There are no changes in the vision. 
7.Malam 
           In Karappan some patients have constipation. 
8.Moothiram 
❖ Neerkuri (Physical examination of urine) 
Urine is collected after taking a well-balanced diet (appetite corrected, seasonally 
correlated), which do not alter the three vital humors. It should be examined within 3-3/4 
Nazhigai. (90 minutes). 
In Neerkuri the Niram (Colour), Manam (Odour), Nurai (froth), Eadai (specific 
gravity) and Enjal (deposits) are noted. 
Apart from these the frequency of urination, abnormal constituents such as sugar, 
protein, presence of blood, pus, and renal crystals must also be found out. In Karappan 
patients straw coloured urine was noticed. 
Neikkuri (oil in urine sign) 
The collected specimen as said above is to be analysed by following method. The 
specimen is kept open in a glass dish or china clay container. It is to be examined under direct 
sunlight, without any shaking of the vessel.Then add one drop of gingelly oil on the surface of 
the urinary specimen and the Neikkuri was noted in direct sunlight, and conclude the diagnosis 
as follows:  
1. Character of  Vathaneer: 
 When the oil drop lengthens like a snake, it is called “VaathaNeer”. 
2. Character of  Pithaneer:  
When the oil drop spreads like a ring, it is called “PithaNeer”. 
3. Character of KabaNeer: 
 
 When the oil drop appears like a pearl, it is called “KabaNeer”. 
4. Character of  ThonthaNeer: 
Snake in the ring, ring in the snake, snake in the pearl and ring in the pearl are the 
characters of ThonthaNeer. 
 In Karappan the Neikkuri was VaathaNeer, PithaNeer and KabaNeer.     
NOI KANIPPU VIV AADHAM (DIFFERENTIAL DIAGNOSIS): 
❖ fhshQ;rf gil ( Psoriasis) 
     Psoriasis is a chronic papulosquamous disorder of unknown etiology. It is charecterised by 
➢ Papular and plaque lesions with silvery white micaceous scales. 
➢ It predominently affects the extensor aspects of extremities and lumbosacral 
area. 
❖ Gz;luPff; Fl;lk; 
“$LNk jhkiuapd; g+tpjo; Nghy; 
  Ftpe;J NkfWg;NghL ntSg;G khFe;  
NjLNk rptg;Ggy tz;z khFe; 
  jpdTkpf thuhJ nrhidapw; gd;dPu; 
thl;LNk ma;apZw; gj;jpahfp 
  tUj;jkpf Tz;lhfp NehT khFk; 
NghLNk ruPuq;fs; Kfq;fs; fhJ 
  Gz;luPff; Fl;lj;jpd; GJikjhNd” 
- A+fp itj;jpa rpe;jhkzp 
Symptomized by 
❖ Erythema 
❖ Itching  
❖ Hypo and Hyper pigmentation 
 
LINE OF TREATMENT: 
In Siddha system of medicine, the main aim of the treatment is to cure the disease by 
removing the root cause. Treatment is not only for perfect healing but also for prevention and 
rejuvenation. 
   
-  jpUts;Stu;                                                                                                                                                                                           
Thiruvalluvar says in “Thirukkural” about physician’s duty to study the disease, study 
the cause, seek subsiding ways and do what is proper and effective. 
In Siddha system, the line of treatment consists of: 
• Neekkam (Treatment) 
• Niraivu (Rejuvenation of wellbeing) 
• Kaappu (Prevention) 
Rules for healthy living has been quoted in Patharthaguna chinthamani as follows, 
Food items inducing Karappan as mentioned in Siddha literature are”- 
         ‘ ngUFQ; NrhskpWq;Fk; ngUk;fk;G 
  tuFfhUld; thioapd; fhnahL 
  ciunfhs; ghfw; nfspw;WkPd; cz;bby; 
  tpuptjha;f; fug;ghD kpFe;jNj’  
- rpj;jkUj;Jtk; rpwg;G 
Nrhsk; 
      ‘Nrhsnkdg; Ngu;gilj;j NrhWfsp dhYlypy; 
  kPsr; nrhwp rpuq;F tpu;j;jpajhk; - ehSq; 
  fug;ghDk; cz;lhk; fdkUe;Jk; ghohk; 
  gug;gida fzkhdNj! ghu;’ 
- mfj;jpau; Fzthflk; 
fk;G  
  ‘fk;G Fspu;r;rpnad fhrpdpapw; nrhy;Ytu;fhz; 
        gk;G nrhwprpuq;ifg; ghypf;Fk; - ntk;Gk;’ 
- mfj;jpau; Fzthflk; 
 
tuF  
         ‘vwpfgj;Njh NlgyNeh naa;Jk; twl;rp 
  nrhwprpuq;F gpj;je; njhlUk; - epiwAq; 
  fufnkdg; g+upj;j fr;RKiy khNj! 
  tufupr; Nrhw;why; tOj;J” 
- mfj;jpau; Fzthflk; 
- mfj;jpau; Fzthflk; 
- mfj;jpau; Fzthflk; 
- mfj;jpau; Fzthflk; 
Consumption of maize, pearl millet, kodo millet, unripened banana, bitter guord may 
cause Karappan disease especialy those who already had the history of allergy. 
 
Because as Saint Therayar said increased level of vatham may aggravate the symptom. 
❖ First line of treatment is taking pergative medicine. 
❖ Then only start the internal and external medicine . 
❖ To change the food habits of the patient. 
Then take easy digestable food which does not aggravate the symptoms of the patient and 
the same food which strengthen the udal thathukkal ( seven body constituation). 
 
MODERN ASPECTS  
SKIN ANATOMY    
Introduction: 
      The skin covers the entire external surface of the human body and is the principal site 
of interaction with the surrounding world. It serves as a protective barrier that prevents internal 
tissues from exposure to trauma, uv radiation, temperature extremes, toxins and pathogenic 
organisms like bacteria. Other important functions include sensory perception, immunologic 
reaction, thermo regulation and control of invisible fluid loss. The integrity has three layers 
1) Epidermis 
2) Dermis 
3) Hypodermis 
Epidermis: 
      The epidermis is continually renewing, stratified, squamous epithelium that keratinizes 
and gives rise to derivatives structures called appendages. The majority of the cells in the 
epidermis are the keratinocytes. It has 5 layers. They are from above downwards 
1) Stratum corneum 
2) Stratum lucidum 
3) Stratum granulosum 
4) Stratum spinosum 
5) Stratum germanativum 
 
Dermis: 
   The dermis is formed by connective tissue having fibers and ground substances. It 
varies in thickness. The dermis can be divided into an upper papillary dermis that interdigitates 
between the rete ridges and the deeper reticular dermis recognized by the thicker, aggregated 
bundles of collagen. Collagen and elastic fibers are synthesized by fibroblasts. Collagen 
contributes about 70% of the dry weight of the dermis and is the most common protein in the 
body. It serves as major structural element of skin and has remarkable tensile strength. Groung 
substances is an amorphous material that consists mainly of water, electrolytes, proteins and 
mucopolysaccharides. These following structures lying in the dermis. 
1) Epidermal appendages 
2) Blood vessels and lymphatics 
3) Nerves muscles 
4) Cells – mast cells, fibroblasts, pericytes, etc., 
Dermo-epidermal junction: 
      It is the basement membrane zone that welds the epidermis to underlying dermis. This 
junction is undulated, forming dermal papillae and rete ridges. 
Epidermal appendages: 
1) Pilosebaceous unit 
2)  Sweat glands 
3)  Nail unit  
Pilosebaceous unit: 
      It consists of a hair follicle containing hair and sebaceous glands opening into follicular 
canal of hair follicle. Sebaceous gland are lipid secreting holocrine glands. They are distributed 
all over the body except the palm and soles with their maximum density in seborrheic area of 
the body hair structure consists of cuticle, cortex, and medulla. These keratinous fibers are of 
two types in adults. Terminal hairs are thick, pigmented and long and are seen on the scalp, 
eyebrows, axillae, genital areas, etc., vellus hairs are small in diameter, short and nonpigmented 
and therefore difficult to discern. 
Sweat glands:  There are 2 types of sweat glands 
1) Eccrine glands 
2) Apocrine glands 
Eccrine glands: 
These are merocrine glands with tubular structures, which open onto the skin directly. 
Sweat glands are present on the entire surface of the body except the lip, external ear canal and 
labia minora and are most abundant on the palms, soles, forehead and axillae. 
Apocrine glands: 
      These tubular glands consist of two main parts the coiled secretary gland and the 
straight excretory duct which opens into the follicular canal just above the openings of 
sebaceous glands. They are distributed along the mammary line e.g. Axillae, areolae, 
periumbilical area, mons pubis and genital and peri anal areas. 
Nail unit: 
     It is yet another epidermal appendages. It consists of nail matrix just underneath the 
proximal nail fold which gives rise to nail plate a keratinized structure. The distal portion of 
the nail matrix is visible usually in thumbnail as nail bed and is bounded on two sides by lateral 
nail fold. 
ECZEMA 
DEFINITION: 
 Eczema is a non - contagious chronic skin disease which is characterized by erythema, 
scaling, oedema, oozing and vesiculation. The word eczema seems to have originated from the 
Greek word ‘ekzein’ meaning "to boil over" or “to effervesce”. Dermatitis comes from the 
Greek word for skin – and both terms refer to the same skin condition. The term dermatitis and 
eczema are generally regarded as synonyms still some authors use the term dermatitis to 
include all types of cutaneous inflammation. Not all dermatitis is eczematous. 
HISTORY: 
 The term "atopic dermatitis" was coined in 1933 by Wise and Sulzberger 
EPIDEMIOLOGY: 
 Eczematous diseases are very common with an estimated prevalence of more than 10% 
in the general population. According to health statistics 15-25% of all dermatological patients 
suffer from eczema. Globally eczema affected approximately 230 million people as of 2010 
(3.5% of the population). In India low prevalence in northern and eastern part of country (0.42-
0.55). ISSAC (International Study of Asthma and Allergies In Childhood) shows prevalence 
between 2.4% - 6%. Regarding contact dermatitis in general population the suffers are more 
than 1% and in construction workers more than 45%. For the age group 6 to 7 years, the 
prevalence of current eczema ranged from 0.9% in India. 
AETIOLOGY: 
 The causes of eczema are unknown. Effective eczema management requires a 
combination of prevention and treatment. In addition to preventing eczema flare-ups by 
minimizing any known triggers, treatment is also an important part of eczema management. 
Basically, two factors cause dermatitis and eczema. 
• Allergic or sensitive skin. 
• Exposure to an irritant. 
The dermatologist Darier has said that, “There is no eczema but an eczematous patient”. 
The general predisposing causes are Age, Genetic and familial predisposition, General debility, 
Climate, Psychological stress, Local Factors, Food as allergens. 
Age: 
Eczema sometimes occurs in infancy, at puberty and at the time of menopause. 
Genetic & familial predisposition: 
There is usually a personal or family history of allergy, viz asthma, eczema and hay 
fever. 
General debility: 
Lowering of resistance of the individual in general debility predisposes to eczema. 
Climate: 
Climate extremes like heat and severe cold. 
Local factors: 
• Xeroderma or ichthyosis, greasy skin, hyperhidrosis, varicose veins. 
• Direct contact with pet and domestic animals. 
• The frequent use of soaps and cleaning products that tend to affect the shiny 
nature of the skin. 
Animal sources: 
● Cow’s milk, Egg white is the allergising factor, any species of fish, meats of all 
kinds can be responsible for allergic reactions. 
Plant sources 
● Wheat flour – allergic reaction due to wheat gluten. 
● Peas, beans and lentils, consumption of edible mushrooms, vegetables such as 
brinjal, carrot, spinach, cabbage, onion, garlic, sweet potato, cauliflower and 
pumpkin cause allergy in some individuals. 
● Among the fruits, strawberries, bananas, oranges, grapes and apples are the 
principal offenders. Occasionally by pears, cherries, plums, gooseberries, Citrus 
fruits and tomatoes may cause atopic allergy. 
Cosmetics: 
Common ingredients in cosmetics such as perfumes, facecreams, deodorants, hair 
dye, shampoos, parabens, benzocaine, lanolin, thimersol, etc. 
Clothing:      
Rubber chappals, spectacle, resins, frames, furs, nylon, synthetic dyes. Most   
buttons of    formaldehyde resins, epoxy resins are all common sensitizers. 
Medicaments:   
This include Sulphonamides, Penicillin, Streptomycin, Cocaine, Tincture benzoin, 
Neomycin, Furacin, Phenargan cream & sticking plaster etc. Dettol, savlon, cetavlon are 
primary irritants. 
INDUSTRIAL AND OCCUPATIONAL  AGENTS     
• Agriculturists   - Plants, weeds, fertilizers, oils. 
• Automobile   - Oil, petrol, solvent, grease, paints, thinner. 
• Building workers   - Cement, lime, paints, insecticides, kerosene oil. 
• Chemical, Pharmaceutical  - Dyes, Chemicals, explosives, solvents, 
                   industries                                  disinfectants, detergents  
• Housewives   - Soaps, detergents, vegetables, fruits, nickel, 
 polishes, artificial flavours, dyes, flowers. 
• Nurses and Doctors  - Iodine, streptomycin, chlorpromazine, tincture. 
• Painters    - turpentine, paints, detergents 
• Plastic factory workers  -resins, hardeners, solvents, glass, cellulose                             
• Rubber workers   -  T.M.T, M.B.T, dyes, glues, oils 
• Tannery workers   - Chromate, arsenic, alkalis, acids. 
• Textile workers   - Formaldehyde, solvents, dyes, bleaches. 
 Scratching, Chemical trauma, Climate, Stress and Strains keep the process going 
with the result that eczema becomes chronic. In practice mixed eczemas are much more 
common than pure entities. History and clinical observation are very important in establishing 
the exact etiological diagnosis. 
IMMUNOLOGY: 
Immunology deals with the body’s response to antigenic challenge. Sensitization 
develops when a different clone of T-lymphocytes is activated. The sensitized T-lymphocytes 
yield two sub populations of lymphocytes. Memory cells those are responsible for the 
persistence of contact allergy. Effector cells that initiate the allergic response when 
appropriately challenged. 
PATHOPHYSIOLOGY: 
❖ Allergy & hypersensitivity: 
The body behaves in a particular way when it is exposed to a chemical substance known 
as ‘Allergen’ for the first time, but changes the nature of its reaction when it is exposed for the 
second and subsequent times. This change is due to proteins known as antibodies. The moment, 
the allergen IgE combination stimulates the mast cells which unload their chemical contents 
into the surrounding tissues. These chemicals (mediators of allergy) cause the manifestations 
of allergy such as erythema, wheal and flare reaction. Flare is due to dilatation of arterioles by 
local axon reflex and the liberation of vasodilator substances like histamine and its byproducts 
like serotonin, bradykinin, acetylcholine from the injured cells like mast cells and basophils 
etc. The manifestation of hypersensitivity may be immediate (or) delayed type. 
❖ Cutaneous Allergy: 
In the skin two important but different allergic reactions occur. 
  Dermal reaction 
• Dermal reaction is commonly seen in urticaria. Allergic reaction takes place in the 
dermis. Intra dermal tests (scratch) show reactivity. 
• The causative antigen reaches the skin through ingestion, inhalation or injection of 
protein substances and the reacting antibodies circulate in the serum. 
 
Epidermal reaction 
• It is seen in allergic dermatitis or eczema. 
• The  causative  substance  reaches  the  skin  by  contact. Intra   dermal  allergic  tests 
are negative, but patch test shows reactivity 
• Allergen + Epidermal protein – Antigen formation (probably in lymph glands) 
• Allergen + Antibodies – Eczematous reaction (In epidermis) 
• A severe local reaction may result in auto-intoxication & dissemination of eczematous 
reaction to distant  parts. 
❖ Status Eczematicus 
It is believed that in case of severe allergic states, a state may develop when the patient 
becomes hypersensitive to even unrelated substances resulting in status eczematicus 
comparable to status asthmaticus in practice of internal medicine. 
Reaction time 
It is the time taken by a sensitized individual to manifest a clinical reaction following 
contact with a known sensitizer. It is usually 12-24 hours but may vary from one hour to 120 
hours. 
Dissemination reaction 
It is a fleeting erythematous macular reaction involving the face and flexures, caused 
by the escape of lymphokines in the circulation resulting in vasodilatation at distant site. 
Clinical Features 
Eczema is characterized by superficial inflammatory oedema of the epidermis 
associated with vesicle formation. Itching varies from mild to severe paroxysms which may 
even interfere with work and sleep. It can differ in severity, frequency and duration among 
individuals. Flare-ups, however, can be unpredictable throughout lifetime. 
Skin areas affected by eczema can exhibit a variety of characteristics including: 
• Blistering 
• Darkening of the area of skin affected by eczema (hyperpigmentation) 
• Dryness 
• Flaking 
• Inflammation (swelling, irritation and warmth) 
• Scaling 
• Small red bumps 
• Thickening of the affected skin due to frequent scratching. Scratching the area affected 
by eczema generally does not relieve the itching and can lead to increased 
inflammation, more intense itching, and harder scratching. 
TYPES: 
❖ Acute Eczema: 
Acute eczema is accompanied by exudative erythema, oedema, and sometimes 
vesicles. It is newly produced eczema, only several days after its onset. Intercellular oedema 
(spongiosis), intense dermal oedema, and inflammation occur.  
❖ Subacute Eczema   
Subacute eczema has a severity between that of acute and that of chronic. Such eczema 
is accompanied by erythema and edema, and it is slightly lichenoid. Mild edema is produced 
in the epidermis. Acanthosis and parakeratosis are observed. 
❖ Chronic eczema 
         Chronic eczema is characterized clinically by lichenification. When acute eczema 
continues for more than one week after onset, it is likely to appear lichenified, and the diagnosis 
is chronic eczema. Acanthosis and parakeratosis are noticeable histopathologically. However, 
there is less infiltration of inflammatory cells into the epidermis than with acute and subacute 
eczema. 
CLASSIFICATION: 
➢ Contact dermatitis 
➢ Atopic eczema 
➢ Seborrheic eczema 
➢  Nummular eczema 
➢ Asteatosis eczema 
➢ Stasis eczema 
➢ Autosensitization dermatitis 
➢ Wiskott-Aldrich syndrome 
1. CONTACT DERMATITIS 
Contact dermatitis is localized to the site of extrinsic stimulation by foreign substance 
or allergic reaction. Eczema reactions such as reddening and blistering occur at the contact 
site.There are specific types of contact dermatitis, such as diaper dermatitis and housewive’s 
hand eczema. The causative substances include certain plants, chemical agents, and nickel, 
mercury and other metals. 
Clinical features 
Erythema, serous papules, vesicles, erosions and crusts are localized at the contact site 
of the causative agent . The eczematous lesions are relatively sharply circumscribed and are 
intensely itchy. Although only localized areas are affected, erosive lesions may become 
widespread when the causative agent is spread by rubbing and scratching. If the inflammation 
spreads over the entire body, systemic symptoms such as fever may arise. When the causative 
agent is highly stimulative, it may cause necrosis of the skin and ulceration. 
Pathogenesis 
Allergic contact dermatitis basically occurs as a type IV allergic reaction. The causative 
agent invades the body percutaneously and is captured by Langerhans cells. It moves to the 
regional lymph nodes and transmits information about the antigen to thymus derived T cells, 
and they proliferate in the lymph nodes. If the causative agent reinvades the body after 
sensitization, the sensitized T cells become activated to release various cytokines, which leads 
to a prompt inflammatory reaction that causes dermatitis. This reaction is not produced by the 
first contact, but it is produced in previously sensitized persons even by contact with a minute 
amount of the antigen.  
2. ATOPIC DERMATITIS 
Atopic dermatitis is chronic eczema/dermatitis caused by an atopic condition (allergic 
asthma, rhinitis, conjunctivitis). Exudative eczema occurs on the face and ear pinna. It is 
characterized by eruptions of dry pityriatic scales.The patient tests positive for white 
dermographism.  
Atopic dermatitis is classified into three age periods: infantile (age 2 months to 4 years), 
childhood (early childhood to puberty), and adolescent/adult.  
 
A) Infantile atopic dermatitis: 
In the early stage of atopic dermatitis in infancy, erythema, scales, and serous papules 
are produced on the head and face and these gradually spread to the trunk. The condition 
becomes exudative: erosions form with crusts and scales attached to the surface. It resembles 
seborrheic dermatitis. Thick crusts on the head and ear notch, and lesions around the mouth 
and lower jaw are also observed. The trunk and extremities become dry, and follicular papules 
aggregate, appearing as goose bumps. Scaly erythematous plaques form on these lesions and 
progress to childhood atopic dermatitis.  
B) Childhood atopic dermatitis 
In childhood atopic dermatitis the skin becomes dry. Lichenified plaques occur on the 
cubital fossa and popliteal fossa. Cracks are often found in the auricle area (ear notch). Multiple 
follicular papules occur on the dry skin of the trunk. This dermatitis is accompanied by intense 
itching, and it progresses quickly to eczematous crusty lesions. 
C) Adolescent and adult atopic dermatitis 
The symptoms are similar to those in childhood dermatitis, but the lichenoid plaques 
progress and enlarge. Rough, dry, dark brown atopic dermatitis occurs all over the upper body. 
The lesions are more severe and widely distributed than those of childhood dermatitis. 
Thinning of one-third of the lateral eyebrow is present. In serious cases, diffuse erythema 
occurs on the face, and a mottled appearance is seen on the neck and upper chest (poikiloderma 
lesion, dirty neck). Atopic prurigo may occur repeatedly on the extremities. 
Pathogenesis: 
A defective skin barrier is important for the pathogenesis of atopic dermatitis. Filaggrin 
gene mutations have been shown to be a key predisposing factor for atopic dermatitis. 
Dyshidrotic and decreased content of lipid in the horny cell layer, facial pallor, dry skin and 
multiple small follicular papules are present (atopic skin). The atopic skin is vulnerable to 
extrinsic irritation; intensely itchy eczema is easily produced by slight irritation, or even by 
perspiration or contact with animal fur, wool or chemicals. 
Immune function abnormality:  
Atopic conditions such as allergic asthma, allergic rhinitis, conjunctivitis and atopic 
dermatitis are found in the family and patient’s history. Patients with atopic dermatitis readily 
produce IgE antibodies. There is a high IgE value and positive intracutaneous reactions to 
various allergens. 
3.SEBORRHEIC DERMATITIS 
  Seborrheic dermatitis occurs on sites of skin where sebum is actively secreted. It is 
characterized by erythematous lesions accompanied by yellowish scales. This is one of the 
most common skin diseases, occurring in infants, adolescents and adults. Pityrosporum fungus 
resident in the skin is a factor in the occurrence. 
Clinical features 
  There is some controversy as to whether seborrheic dermatitis in infants, adolescents 
and adults is the same disease, because there are minor differences in the clinical courses. 
Dermatitis appears as follicular eczema on seborrheic sites or intertriginous areas in the head, 
face, axillary fossa, neck and external genitals. The main features of the lesions are oleaginous 
scales and erythematous plaques that may be slightly itchy. 
In infants, yellowish crusts begin to form on the scalp, eyebrows and forehead. In 
infants, scaly erythematous plaques may also from 2 to 4 weeks after birth. In most cases they 
resolve 8 to 12 months after birth. In adolescents and adults, pityroid scales increase and scaly 
erythematous lesions form on the eyebrows and nasolabial groove. Seborrheic dermatitis is 
chronic and recurrent. 
Pathogenesis: 
Triglycerides in sebum are decomposed by microbes resident in the skin to produce free 
acid. The free acid reacts to cause seborrheic dermatitis. It has been reported that over 
proliferation of  Pityrosporum fungi such as Malassezia furfur aggravates seborrheic dermatitis. 
4. NUMMULAR ECZEMA (ECZEMA NUMMULARE) 
            Round, relatively large eczematous plaques are produced. Nummular eczema may 
occur at any site on the body, and it tends to progress to autosensitization dermatitis. 
Clinical features: 
Nummular eczema is frequently seen in the winter. Multiple round eczematous lesions 
occur, mostly on the extremities (particularly on the extensor surface of the lower extremities), 
trunk, hips and buttocks. At the periphery of the lesions, serous papules aggregate, in the center 
of which exudative erythema is produced with scales on the surface. Most cases are 
accompanied by intense itching and multiple scars from rubbing and scratching. As the lesions 
progress, they may produce dispersal eruption to progress into autosensitization dermatitis. 
Pathogenesis: 
Scratched insect bites may develop urticarial lichens that, when rubbed, progress to 
nummular eczema, or nummular eczema may result from asteatotic eczema in the elderly, or  
it may appear as a symptom of atopic dermatitis. 
5. LICHEN SIMPLEX CHRONICUS 
Synonyms: Lichen Vidal, Circumscribed neurodermatitis 
Lichen simplex chronicus is chronic eczema in which round, intensely itchy lichenified 
plaques form on the nuchal region and extensor aspect of forearms and lower legs of middle-
aged women. Pigmentation or depigmentation is present in many cases. Warty eruptions may 
proliferate. When skin is repeatedly stimulated by the friction of clothing or by metal allergens 
and the site is rubbed and scratched for a long period of time, it leads to the occurrence of 
chronic eczematous lesions.  
6. AUTOSENSITIZATION DERMATITIS 
           Multiple small papules and erythematous lesions accompanied by itching occur 
systemically. They are caused by sudden aggravation of a localized lesion. This dermatitis is 
caused by endogenous allergic reaction. 
Clinical features: 
Reddening, swelling and acute aggravation of exudation occur in the lower extremities 
as primary lesions of autosensitization dermatitis (in 50% to 60% of cases). Two weeks to 
several weeks after acute aggravation of reddening, swelling and exudation, dispersed 
eruptions appear. In most cases, the eruptions are erythema, papules, serous papules, or 
pustules of 2 to 5 mm in diameter dispersed symmetrically on the extremities, trunk, and face. 
These are often accompanied by intense itching. Systemic symptoms such as fever and fatigue 
may occur. 
Pathogenesis:   Autosensitization dermatitis arises from endogenous allergic reaction. 
Decayed proteins, bacteria, fungal components, and toxins produced by injured tissues in a 
primary lesion are considered to be the antigens. These may spread through the entire body 
such in blood flow from the primary lesion, or they may spread by rubbing or by an accidental 
dose of the causative substance (orally or intravenously). Autosensitization dermatitis is caused 
by sensitization against the antigens. The primary lesions can be nummular eczema, stasis 
dermatitis, contact der-matitis, atopic dermatitis, tinea pedis, or eczematisation of a burn. 
7. STASIS DERMATITIS: 
Oedematous erythema or eczematous plaques form on the lower thighs as a result of 
varicose veins or congestion in the lower extremities. This disease tends to affect those who 
work standing, the elderly, and obese women. It may progress to autosensitization dermatitis.  
Clinical features: 
Edematous erythema occurs on the lower third of the leg, particularly at the upper 
ankles. The site gradually presents a dark red, scaly, eczematous plaque, pigmentation or 
whitish atrophie blanche. Minor trauma may induce ulceration. Treatments for stasis dermatitis 
may induce allergic contact dermatitis as a complication, from the application of an antiseptic 
or a topical agent. Aggregated serous papules often progress to autosensitization dermatitis. 
Pathogenesis: 
Congestion in the cutaneous blood vessels is caused by impairment of venous outflow, 
which leads to bleeding from the capillary vessel loop in the dermal upper layer. Hemosiderins 
deposit in tissues, and the skin takes on a blackish-brown appearance. The keratinocytes are 
injured by further impairment of blood flow. Atrophy and scaling occur in the epidermis and 
there is tendency of ulceration. The skin loses its function as a barrier and becomes more 
reactive to extrinsic irritation, leading to eczematous lesions in many cases. 
8. ASTEATOTIC ECZEMA 
Skin dryness (asteatosis, ketosis) occurs when sebum decreases as a result of aging or 
excess washing. When the horny cell layer is destroyed, the skin is vulnerable to extrinsic 
irritation. When asteatosis becomes inflamed and eczematous, the condition is called asteatotic 
eczema. This mostly affects the lower extremities of elderly in dry seasons, especially winter. 
For those who have a habit of excessively washing or rubbing the body with a towel, lifestyle 
guidance to avoid such behavior has therapeutic effects. Use of moisturizer prevents skin 
dryness. 
 
9.WISKOTT-ALDRICH SYNDROME 
The three major characteristics of this disorder are immunological deficiency (T-cell 
dysfunction), thrombocytopenia, and intractable eczema. It is hereditary (X-linked recessive). 
There are decreased levels of immunoglobulins. Bone marrow transplantation may be 
performed. 
Clinical features: 
          Wiskott-Aldrich syndrome is characterized by eczema or purpura that occurs in newborn 
babies within 6 months after birth. The eczema that occurs on the head, face, buttocks and 
extremities appears similar to atopic dermatitis and seborrheic dermatitis. Purpura is caused by 
thrombocytopenia. Immune-deficiency-derived infections occur repeatedly as the patient 
grows. Infections are caused by various factors including bacteria viruses, fungi and protozoa. 
Impetigo contagiosa (Staphylococcal infection), pseudomonas infection, herpes simplex, 
varicella (herpes virus infection), and candidiasis are particularly likely to accompany this 
syndrome, and they tend to become aggravated and persistent. Systemic symptoms such as 
bloody diarrhoea, internal organ hemorrhage, infection (e.g. tympanitis, paranasal sinusitis, 
pneumonia) are seen recurrently. 
INVESTIGATIONS OF ECZEMA 
Patch test 
Patch tests detect type IV (delayed or cell-mediated ) hypersensitivity. It is common 
practice for a battery of around 20 common antigens, including common sensitizers such as 
nickel, rubber and fragrance mix to be applied to the skin of the back under aluminium discs 
for 48 hours. The sites are then examined for a positive reaction 24 hours later and possibly 
again a further 24 hours later. The positive test is revealed by the development of an eczematous 
patch with erythema swelling and vesicles at the site of application. 
Patch test reaction is graded in the following degrees, 
+ - Only redness 
++ - Marked redness and swelling 
+++ - Marked redness, swelling and papules 
++++ - redness, oedema and vesicles 
Specific IgE levels to antigens can be measured in serum by a specific radio allergic sorbent 
test (RAST). These are occasionally performed to support diagnosis of atopic eczema and to 
determine specific environmental allergens, eg. pet dander, horse hair, house dust mite, pollens 
and foods. 
Prick tests 
Prick tests are a way of detecting cutaneous type I (immediate) hypersensitivity to 
various antigens such as pollen, house dust, mite or dander. 
Bacterial and viral swabs for microscopy and culture 
These are useful tests in suspected secondary infection skin swabs for bacteriological 
assessment will invariably reveal the presence of bacteria. In the case of recurrent impetigo in 
a child with atopic eczema, bacterial swabs should be taken from carrier sites (axillae and groin) 
from both the affected individual and house hold members. 
 
PREVENTION: 
People with eczema should not get the smallpox vaccination due to risk of 
developing eczema vaccinatum, a potentially severe and sometimes fatal complication. 
 
 
 
 
 
 
 
 
      
 
 
 
 
   DRUG REVIEW 
INTERNAL MEDICINE:  
Parangisakkai Chooranam   
Ingredients:  
❖ Parangichakkai (Smilax china)   3 palam (105 gms) 
❖ Chukku (Zingiber officinale)    3 varagan(12.6gms) 
❖ Thippili (Piper longum)    3 varagan(12.6gms) 
❖ Elam (Elettaria cardamomum)   3 varagan(12.6gms) 
❖ Vaivilangam (Embelia ribes)    3 varagan(12.6gms) 
❖ Sannalavanga pattai (Syzygium aromaticum)             3 varagan(12.6gms) 
❖ Omam (Carum copticum)    3 varagan(12.6gms) 
❖ Kurosani omam (Hyoscyamus niger)   3 varagan(12.6gms) 
❖ Sithiramoolaver pattai ( Plumbago zeylanica) 3 varagan(12.6gms) 
❖ Sitrarathai (Alpinia officinalis)   3 varagan(12.6gms) 
❖ Modi (Piper longum root)    3 varagan(12.6gms) 
❖ Perarathai (Alpinia galanga )    3 varagan(12.6gms) 
❖ Siruthekku (Clerodendrum serratum)  3 varagan(12.6gms) 
❖ Dhaniya (Coriander sativum)    3 varagan(12.6gms) 
❖ Seeragam (Cuminum cyminum)   3 varagan(12.6gms) 
❖ Karunseeragam (Nigella sativa)   3 varagan(12.6gms) 
❖ Athimathuram (Glycyrrhiza glabra)   3 varagan(12.6gms) 
❖ Vettiveer (Vettiveria zizanoides)   3 varagan(12.6gms) 
❖ Vilammicham ver(Plectranthus vetiveriodes) 3 varagan(12.6gms) 
❖ Muthakkasu(Cyperus rotundus)   3 varagan(12.6gms) 
❖ Kichili kizangu(Curcuma zodoaria)   3 varagan(12.6gms) 
❖ seeni (sugar)      Equal quantity 
INTERNAL MEDICINE 
1.PARANGIPATTAI 
Botanical name :  smilax china 
Family  :  liliaceae 
Used parts  :  tuber 
Organoleptic character 
Taste   :  inipu 
Potency  :  thatpam 
Division  :  inipu 
 “jhfk; gythje; jhJel;lk; Gz;gpsit 
Nkfq; fbfpue;jp tPo;%ye; -NjfKld; 
Fl;il gfe;jNkw; nfhs;kdk; Nghk;gwq;fpg; 
gl;ilapid Ar;rhpj;Jg; ghh;”              -Njuah; Fzthflk; 
Action: 
       Anti syphilitic 
Anti vatham 
Constituents : 
 Saponins 
,Herbal steroids 
 
SUKKU 
Botanical name :  Zingiber officinale 
Family  :  Zingiberaceae 
Used parts  :  Rhizome 
Organoleptic character 
Taste   :   Karppu 
Potency  :  veppam 
Division  :  Karppu 
 
                                                      -
 
 
Action: 
          Stimulant, Stomachic, Carminative 
Constituents: 
        Calcium sulphate, calcium carbonate, phellandrene, gingerol. 
THIPPLI
 
Botanical name :  Piper longum 
Family  :  piperaceae 
Used parts  :  dried unripe fruit 
Organoleptic character 
Taste   :  Karppu 
Potency  :  Veppam 
Division  :  Karppu 
 “Mrdtha; njhz;il Neha; Mtuz gpj;jKjy; 
Ehtrptpop fhjpitNeha; ehl;GONeha; -tPrpLtp 
aq;fyhQ;r; dQ;rpijAk; mk;gha; 
moptpe;Jk;nghq;fyhQ;r eq;ifah;Nfhl; Nghy;” 
Chemical constituents : 
Resin,Volatile oil,Starch,Fatty oil and Piperine. The fruits contain 1%volatile 
oil, resin, a waxy alkaloid, piperlongumin. 
 
 ELAM 
Botanical name :  Elettaria cardamomum 
Family  :  Zingiberaceae 
Used parts  :  Seed 
Organoleptic character 
Taste   :  Karppu 
Potency  :  Veppam 
Division  :  Karppu 
Action: 
      Stimulant, Carminative, Stomachic. 
Constituents:      
      Volatile oil,cineol, limonene. 
-
     VAIVILANGAM 
Botanical name :  Embelia ribes 
Family  :  Primulaceae 
Used parts  :  Seed 
Organoleptic character 
Taste   :  Kaippu 
Potency  :  Veppam 
Division  :  Karppu 
Action: 
      Anthelmintic, Carminative, Stomachic, Stimulant. 
Constituents: 
Embolic acid, volatile and fixed oil, resin, alkaloid 
      -
 
 SITRARATHAI 
Botanical name :  Alpinia officinarum 
Family  :  Zingiberaceae 
Used parts  :  Rhizome 
Organoleptic character 
Taste   :  Karppu 
Potency  :  Veppam 
Division  : Karppu 
Action: 
     Expectorant, Febrifuge, Stomachic. 
Constituents: 
     Galangol, galangin. 
 PERARATHAI 
Botanical name :  Alpinia galanga 
Family  :  Zingiberaceae 
Used parts  :  Rhizome 
 
Organoleptic character 
Taste   :  Karppu 
Potency  :  Veppam 
Division  :  Karppu 
Action: 
Expectorant, Febrifuge, stomachic. 
Constituents: 
Campheride, galangin, alpinin. 
        -
 
OMAM 
 
Botanical name :  Carum copticum 
Family  :  Apiaceae 
Used parts  :  Seed 
Organoleptic character 
Taste   :  Karppu 
Potency  :  Veppam 
Division  :  Karppu 
Action: 
      Stomachic, Antispasmodic, Carminative, Antiseptic 
Constituents: 
Volatile oil, thymol. 
       -
KUROSANI OMAM 
Botanical name :  Hyoscyamus niger 
Family  :  Solanaceae 
Used parts  :  Seed 
Organoleptic character 
Taste   :  Karppu and Siru Kaippu 
Potency  :  Veppam 
Division  :  Karppu 
Action: 
Hypnotic, Sedative, Anodyne, Mild diuretic. 
Constituents: 
    Fixed oil, gum, starch, hyoscyamine,hyoscine. 
-
SANNALAVANGAPATTAI 
 
Botanical name :  Cinnamomum verum 
Family  :  Laurales 
Used parts  :  Bark 
Organoleptic character 
Taste   :  Karam with Inippu 
Potency  :  Seetham 
Division  :  Inippu 
Action: 
     Stimulant, Carminative, Aphrodisiac. 
Constituents: 
      Cinnamaldehyde, cinnamon oil, cinnamic acid, coumaric acid. 
-
 
 
CHITHIRAMOOLAM 
Botanical name :  Plumbago indica 
Family  :  plumbaginaceae 
Used parts  : Root 
Organoleptic character 
Taste   :  Karppu,kaipu 
Potency  :  Veppam 
Division  :  Karppu 
Actions 
Tonic, stomachic, antiperiodic 
Chemical constiuents 
Plumbagin,Tannins, steroids, glucoside, triterpenes 
- 
SIRUTHEKKU 
Botanical name :  Clerodendrum serratum 
Family  :  Verbenaceae 
Used parts  :  Root 
Organoleptic character 
Taste   :  Kaippu, thuvarppu 
Potency  :  Veppam 
Division  :  Karppu 
Action: 
    Stimulant, Sedative. 
 
KOTHAMALLI 
Botanical name :  Coriandrum sativum 
Family  :  Apiaceae 
Used parts  :  Seed 
Organoleptic character 
Taste   :  Karppu 
Potency  :  Seetham Veppam 
Division  :  Karppu 
Action: 
Stomachic, Carminative, Stimulant. 
Constituents: 
Volatile oil, vitamin C. 
“
 
 
SEERAGAM 
Botanical name  :  Cuminum cyminum 
Family   :  Apiaceae 
Used parts   :  Seed 
Organoleptic character 
Taste    :  Karppu, inippu 
Potency   :  Seetham 
Division   :  Inippu 
Action: 
Carminative, Stimulant, Astrigent, Stomachic. 
Constituents: 
    Thymene, cuminol, cymene. 
- 
KARUNSEERAGAM 
 
Botanical name  : Nigell sativa 
Family   : Rananculaceae 
Used parts   : Seed 
Organoleptic character 
Taste    : Karppu 
Potency   : Veppam 
Division   : Karppu 
Action: 
Stomachic,Carminative,Diuretic 
Constituents: 
Volatile oil,fixed oil 
 
ATHIMATHURAM 
 
Botanical name  : Glycyrryhiyza glabra 
Family    : Fabaceae 
Used parts   : Root 
Organoleptic character: 
Taste    : Inippu 
Potency   : seetham 
Division   : Inippu 
Action: 
Tonic,Laxative,Demulcent 
Constituents: 
glycyrrhizic,glycyrrhetinic acid 
VILAMICHUVEER 
Botanical name : Chrysopogon zizanioides 
Family  : Poaceae 
Used parts  : Root 
Organoleptic character: 
Taste   : kaippu 
Potency  : seetham 
Division  : inippu 
Action: 
Diaporetic,diuretic,febrifuge 
Constituents: 
Volatile oil. 
 
VETTIVER  
Botanical name : Plectranthus vettiveroits 
Family  : Lamiaceae 
Used parts  : Root 
organoleptic character: 
Taste   : kaippu 
Potency  : Seetham 
Division  : inippu 
Action: 
Anti pithaa,Refrigerant 
Constituents: 
Voloatile oil,
 
KICHILIKIZANGU 
Botanical name :  Cyperus rotundus 
Family  :  Cyperaceae 
Used parts  : Leaf,rhizom 
Organoleptic character: 
Taste   : Kaippu 
Potency  : Veppam 
Division  : Karppu 
Action: 
Stimulant,Carminative,Aromatic 
Constituents: 
Curcumin,albuminoids 
VELLAI SAKKARAI (SUGAR) 
nghJFzk;: 
“rPdp rh;f;fiuf;Fj; jPuhj td;RuKq; 
Nfhdpf;Fk; thjj;jpd; $l;LwTk; Vdpw;Fk; 
the;jp nahLfpUkp khwhj tpf;fYNk 
Nghe;jpiria tpl;L;g; GOz;L” 
Indication: 
Vatha suram,vathanoi ,vikkal 
EXTERNAL MEDICINE:  
KARAPPAN ENNAI  
Ingredients: 
❖ Poovarasu    10 palam(350 gms)  
❖ Sengathari   10 palam(350 gms) 
❖ Nilavagai   10 palam(350 gms) 
❖ Kandangathiri   10 palam(350 gms) 
❖ Boothakarappan  10 palam(350 gms) 
❖ Poonaikali   10 palam(350 gms) 
❖ Milagu     1kazhanju(5.1gms) 
❖ Karunseeragam  1kazhanju(5.1gms) 
❖ Karkolam   1kazhanju(5.1gms) 
❖ Vellaipoondu   1kazhanju(5.1gms) 
❖ Vasambu   1kazhanju(5.1gms) 
❖ Sathakuppai   1kazhanju(5.1gms) 
❖ Valamburikai   1kazhanju(5.1gms) 
❖ Parangipattai   1kazhanju(5.1gms 
❖ Amanakku ennai   1 Padi (1344ml) 
❖ Elumichai pala saru  1 Padi (1344ml) 
❖ Vellattu pal   1 Padi (1344ml) 
 
POOVARASU 
Botanical name  : Thespesia populnea 
Family   : Malvaceae 
Used parts   : Leaf,flower,seed,root,park 
Organoleptic character: 
Taste    : Kaippu 
Potency   : Veppam 
Division   : Karpu 
Action: 
Althelmintic,Depurative 
Constituents: 
Musilage 
 
KANDANGATHIRI 
Botanical name  : Solanum surattense 
Family   : Solanaceae 
Used parts   : Leaf,flower,fruit,seed,root 
Organoleptic character: 
Taste    : Karppu 
Potency   : Veppam 
Division   : Karppu 
 
Action: 
Diuretic,expectorant,carminative 
Constituents: 
Carpesterol,Solanocarpine 
 
POONAIKALI 
Botanical name  : Mucuna pruriens 
Family   : Fabaceae 
Used parts   : Seed,root, 
Organoleptic character: 
Taste    : Thuvarppu 
Potency   : Thatpam 
Division   : Inippu 
Action: 
Astringent,diuretic,nervine tonic 
Constituents: 
Mucunine. 
 SATHAKUPPAI 
Botanical name  : Anithum graveolens 
Family   : Apiaceae 
Used parts   : Leaf,flower,seed 
Organoleptic character: 
Taste    : Inippu 
Potency   : Veppam 
Division   : Karppu 
Action: 
Carminative,stimulant,emmenagogue 
Constituents: 
Anethine,apiol,phellandrenne 
VALAMPURIKAI 
Botanical name  : Helicteres isora 
Family   : Malvaceae 
Used parts   : Root,park 
Organoleptic character: 
Taste    : Kaippu 
Potency   : Veppam 
Division   : Karppu 
Action: 
Demulcent,astringent 
AMANAKU 
Botanical name  : Ricinus communis 
Family   : Euphorbiaceae 
Used parts   : Seed 
Organoleptic character: 
Taste    : Kaippu 
Potency   : Veppam 
Division   : Karppu 
Action: 
Anti vadha,Galactagogue 
Constituents:  
Curcin. 
 
ELUMICCHAI 
Botanical name  : Citrus limon 
Family   : Rutaceae 
Used parts   : Leaf,seed,fruit 
Organoleptic character: 
Taste    : Pulippu 
Potency   : Veppam 
Division   : Karppu 
Action: 
Refrigerant,Carminative 
 
SENGATHTHAARIPATTAI 
Botanical name  :     capparis sepiazia   
Family                :     capparidaceae 
Organoleptic character 
Suvai             :      Kaipu 
Thanmai            :     Veppam 
Pirivu                        :      Kaarppu
 
Chemical Constituents: 
Alcoloids, Glycosides, Carbohydrates, Anthocyanins, Sterols,  Terpenes. 
 
NILAAVAARAI 
 Botanical name :     Cassia senna  
Family               :    csesalpinaceae 
Organoleptic character 
Suvai     :     kaippu 
Thanmai    :     Veppam 
Pirivu                :     Kaarppu
General properties: 
“epyhthiu apd;Fze;jhd; ePNfs; kapNy 
gy%y thAntg;G ghitr; -rpyfpue;jp 
nghy;yhj Fd;kk; ngUKkyf; fl;LKjy; 
vy;yh kfw;Wnkd vz;” 
 
VASAMBU 
Botanical name  :     Acorus calamus 
English Name              :     Sweet flag   
Family               :     Araceae 
Organoleptic character 
Suvai             :      Kaarppu 
Thanmai            :     Veppam 
Pirivu                        :      Kaarppu
Chemical constituents 
               Asarone, Calamenol, Calamene, Eugenol, Methyl Eugenol, Pinene, Camphene, 
Calamol, Azulene .  
Actions 
Stimulant, Stomachic, Antiperiodic, Carminative, Emetic, Disinfectant, Germicide     
 
VELLAI POONDU 
Botanical name         :    Allium sativum    
Family          :    Liliaceae 
 
Organoleptic character: 
Suvai             :    Kaarppu 
Thanmai            :    Veppam 
Pirivu             :    Kaarppu 
 
CHEMICAL CONSTITUENTS: 
Allicin, allin, ajoene, vinyldithins, S-allylcysteine, phytoallexinallinase, alistatin, 
glycosides, arginine, diallyldisulphide, dipropyl disulphide,   
ACTIONS: 
Diuretic, Tonic, Alterative, Carminative, Stomachic, Expectorant, Anthelmentic  
 
MILAGU 
Botanical name         :    piper nigram   
Family          :    piparaceae 
Organoleptic character: 
Suvai             :    Kaarppu 
Thanmai            :    Veppam 
Pirivu             :    Kaarppu 
 
 
Chemical constituents 
Piperine, Piperidine, piperetine, Chavicine. 
Actions 
Stimulant, acrid, carminative, rubefacient, antiperiodic, resolvent, anti vadha, 
antidote. 
 
 
 
       
 
 
    MATERIALS AND METHOD 
PRIMARY OBJECTIVE: 
              To compare the efficacy of Parangisakkai Chooranam” (Internal) and Karappan Ennai 
(External)  with and without Yogam  in  Karappan. 
SECONDARY OBJECTIVE:   
1. To study the Siddha basic principles, Envagai Thaervu  in the patients of Karappan . 
2. To study the effectiveness of Yogam in the management of Karappan along with trial 
drug. 
3. To perform Biochemical analysis of the trial drug. 
STUDY DESIGN: 
     An open clinical trial 
STUDY PLACE: 
Ayothidoss  Pandithar  Hospital, 
National  Institute  of  Siddha, 
Tambaram Sanatorium, Chennai-47. 
STUDY PERIOD:  
18   months 
SAMPLE SIZE:     
40 patients (20 patients Trial drugs and Yogam, 20 patients only with trial drugs) 
TRIAL DRUGS:  
Internal Medicine: Parangisakkai Chooranam  
Source of raw drugs: 
 The required raw drugs for the preparation of Parangisakkai Chooranam were procured 
from the Country Medicine shop, Parrys, Chennai.  
Raw drugs Identification and authentication:  
These ingredients were identified and were authenticated by Dr.D.Aravind M.Sc, Asst 
Prof, Medicinal Botanist at NIS, Tambaram sanatorium, Chennai. 
 
Ingredients:  
 Parangichakkai (Smilax china)   3 palam (105 gms) 
 Chukku (Zingiber officinale)    3 varagan(12.6gms) 
 Thippili (Piper longum)    3 varagan(12.6gms) 
 Elam (Elettaria cardamomum)   3 varagan(12.6gms) 
 Vaivilangam (Embelia ribes)    3 varagan(12.6gms) 
 Sannalavanga pattai (Syzygium aromaticum)             3 varagan(12.6gms)  
 Omam (Carum copticum)    3 varagan(12.6gms) 
 Kurosani omam (Hyoscyamus niger)   3 varagan(12.6gms) 
 Sithiramoolaver pattai ( Plumbago zeylanica) 3 varagan(12.6gms) 
 Sitrarathai (Alpinia officinalis)   3 varagan(12.6gms) 
 Modi (Piper longum root)    3 varagan(12.6gms) 
 Perarathai (Alpinia galanga )    3 varagan(12.6gms) 
 Siruthekku (Clerodendrum serratum)  3 varagan(12.6gms) 
 Dhaniya (Coriander sativum)    3 varagan(12.6gms) 
 Seeragam (Cuminum cyminum)   3 varagan(12.6gms) 
 Karunseeragam (Nigella sativa)   3 varagan(12.6gms) 
 Athimathuram (Glycyrrhiza glabra)   3 varagan(12.6gms) 
 Vettiveer (Vettiveria zizanoides)   3 varagan(12.6gms) 
 Vilammicham ver(Plectranthus vetiveriodes) 3 varagan(12.6gms) 
 Muthakkasu(Cyperus rotundus)   3 varagan(12.6gms) 
 Kichili kizangu(Curcuma zodoaria)   3 varagan(12.6gms) 
 seeni (sugar)      Equal quantity 
 
PURIFICATION OF RAW DRUGS: 
Purification of parangi pattai: 
First powder the bark. Take a pot with milk and its mouth is covered with white cloth. 
Then the powder over it and close it with another vessel. Gently heat it for 3 hours then dry 
and grind it.  
Purification of sukku: 
Soaked in lime water for three hours and powder it. 
Purification of thippili 
 Soaked in lime juice, dried it and powdered.   ( Ref: Marunthusei iyalum kalaum) 
Purification of elam 
Dried it and powdered it.   ( Ref: Marunthusei iyalum kalaum) 
Purification of vaivilangam  
Dried it and powdered it.      ( Ref: Marunthusei iyalum kalaum) 
Purification of seeregam 
Dried it and powdered it.   ( Ref: Marunthusei iyalum kalaum) 
Purification of omam 
Dried it and powdered it.   ( Ref: Marunthusei iyalum kalaum) 
 
Purification of kurosani omam 
Dried it and powdered it.   ( Ref: Marunthusei iyalum kalaum) 
Purification of dhaniya 
Dried it and powdered it.    ( Ref: Marunthusei iyalum kalaum) 
Purification of sannalavanga pattai 
Dried it and powdered it.     ( Ref: Marunthusei iyalum kalaum) 
Purification of karunseeragam 
  Soked in lime water for three hours then dried and powdered    
   (Ref:SigichaRathinaTheepam) 
Purification of vettiver 
   Wash it in freash water, dry it and powdered it.     ( Ref: Marunthusei iyalum 
kalaum) 
  Purification of vilamicham  veer 
 Wash it in freash water, dry it and powdered it.    ( Ref: Marunthusei iyalum kalaum) 
Method of preparation:          
Each one of the above mentioned drugs will be purified ,ground into fine powder and 
mixed together . To this quantity equal amount of powdered sugar will be added and mixed 
well.                                      (Reference book : Chikicha Ratna Deepam (Pg No:116 )  
Purification of Chooranam 
Whole chooranam is subjected to pitaviyal. 
 Dosage  :   4.2 gms, twice a day 
         Adjuvant  :  Hot water 
        Duration  :  40days 
 
EXTERNAL MEDICINE:  
Karappan Ennai 
Ingredients: 
I.  
 Poovarasu    10 palam(350 gms)  
 Sengathari   10 palam(350 gms) 
 Nilavagai   10 palam(350 gms) 
 Kandangathiri   10 palam(350 gms) 
 Boothakarappan  10 palam(350 gms) 
 Poonaikali   10 palam(350 gms) 
 These above drugs are ground into coarse powder and (1thooni) 21.5 litres of water is 
added to it   and boiled .It is reduced to ½ of the part(i.e 10.75 litres). 
II. 
 Milagu     1kazhanju(5.1gms) 
 Karunseeragam  1kazhanju(5.1gms) 
 Karkolam   1kazhanju(5.1gms) 
 Vellaipoondu   1kazhanju(5.1gms) 
 Vasambu   1kazhanju(5.1gms) 
 Sathakuppai   1kazhanju(5.1gms) 
 Valamburikai   1kazhanju(5.1gms) 
 Parangipattai   1kazhanju(5.1gms) 
 These above ingredients are ground with goat’s milk. 
III.  
 Amanakku ennai   1 Padi (1344ml) 
 Elumichai pala saru  1 Padi (1344ml) 
 Vellattu pal   1 Padi (1344ml)  
Method of preparation  
All the above ingredients (mentioned in I,II.III) are mixed together and boiled into 
consistency of mezhugu .  
Duration:  40 days 
 
 
Drug storage: 
The trial drug Parangisakkai Chooranam is stored in clean and dry glass bottles and 
Karappan Ennai is stored in clean and dry narrow mouthed bottles. 
Dispensing: 
The Powder is given in packet. Oil is given in pet bottles. 
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BIO - CHEMICAL ANALYSIS OF PARANGICHAKKAI CHOORANAM 
ANALYSED AT NATIONAL INSTITUTE OF SIDDHA 
S.No EXPERIMENT OBSERVATION INFERENCE 
1.  Physical Appearance of sample Dark brown 
*******colourcol
our 
 
2. Solubility: 
a. A little of the sample is shaken well with 
distilled water. 
b. A little of the sample is shaken well with 
con. HCl/ Con. H2So4. 
    Soluble in 
distilled water 
 
 
Presence of 
Silicate 
3. Action of Heat: 
   A small amount  of the sample is taken in a 
dry test tube and heated gently at first and then 
strong. 
White fumes 
evolved 
 
 
 
Presence of 
Carbonate 
 
4. Flame Test: 
  A small amount (500mg) of the sample is 
made into a paste with con. HCl in a watch 
glass and introduced into non-luminous part of 
the Bunsen flame. 
No Bluish green 
flameappeared. 
Absence of 
Copper 
5. Ash Test: 
A filter paper is soaked into a mixture of 
sample and dil. cobalt nitrate solution and 
introduced into the Bunsen flame and ignited 
No Yellow 
coloured flame 
Absence  of 
Sodium 
 
Preparation of Extract:  5 gm of Parangicahkkai Chooranam is weighed accurately and 
placed in a 250ml clean beaker and added with 50ml of distilled water. Then it is boiled well 
for about 10 minutes. Then it is cooled and filtered in a 100ml volumetric flask and made up 
to 100ml with distilled water. 
 
 
 S.No EXPERIMENT 
 
OBSERVATION INFERENCE 
I. TEST FOR ACID RADICALS 
1.  Test For Sulphate: 
a.2ml of the above prepared extract is taken in 
a test tube to this added 2ml of 4% dil. 
ammonium oxalate solution 
Cloudy 
appearance 
present 
Presence  
of  Sulphate 
2. Test For Chloride: 
2ml of the above prepared extracts is added 
with 2ml of dil-HCl is added until the 
effervescence ceases off. 
Cloudy  
appearance 
absence 
absence  
of  Chloride 
3. Test For Phosphate: 
2ml of the extract is treated with 2ml of 
dil.ammonium molybdate solution and 2ml of 
con.HNo3 
Mild  yellow 
appearance  
 
  Phosphate 
mildy present 
4.  Test For Carbonate: 
2ml of the extract is treated with 2ml dil. 
magnesium sulphate solution. 
No Cloudy 
appearance  
absence 
of  Carbonate 
5 Test For Nitrate: 
1gm of the substance is heated with copper 
turning and concentrated H2So4 and viewed 
the test tube vertically down. 
No characteristic 
changes 
Absence  
Of borate 
6 Test For Lead: 
2ml of the extract is added with 2ml of 
dil.potassium iodine solution. 
No Yellow 
Precipitate is 
obtained. 
Absence of 
Lead 
7 Test For Copper: 
a. One pinch(50mg) of substance is made into 
paste with con. HClin a watch glass and 
introduced into the non-luminuous part of the 
flame. 
No Blue colour 
flame 
No Blue colour 
precipitate formed. 
Absence 
of Copper 
 8. 
 
Test For Nitrite: 
3drops of the extract is placed on a filter 
paper, on that-2 drops of dil.acetic acid and 2 
drops of dil. Benzidine solution is placed. 
No characteristic 
changes 
 
Absence  
of  Nitrite 
9. Test For Borate: 
  2 Pinches (50mg) of the substance is made 
into paste by using dil.sulphuric acid and 
alcohol (95%) and introduced into the blue 
flame. 
Bluish green 
colour flame did 
not appear. 
   Absence  
of  Borate 
II. TEST FOR BASIC RADICALS 
1. Test For Lead: 
2ml of the extract is added with 2ml of 
dil.potassium iodine solution. 
No Yellow 
Precipitate is 
obtained. 
Absence of 
Lead 
2. Test For Copper: 
a. One pinch(50mg) of substance is made into 
paste with con. HClin a watch glass and 
introduced into the non-luminuous part of the 
flame. 
 
No Blue colour 
flame 
No Blue colour 
precipitate formed. 
Absence 
of Copper 
3. Test For Aluminium: 
To the 2ml of extract dil.sodium hydroxide is 
added in 5 drops to excess. 
No characteristic 
changes 
  Absence 
of Aluminium 
4. Test For Iron: 
a.To the 2ml of extract add 2ml of 
dil.ammonium solution 
b.To the 2ml of extract 2ml  thiocyanate 
solution and 2ml  of con HNo3 is added 
 
No Red colour 
appeared 
 
Absence of 
Iron 
5. Test For Zinc: 
    To 2m1 of the extract sodium 
hydroxide solution is added in 
drops to excess. 
White precipitate 
is not 
Formed 
 
Absence of 
Zinc. 
 
6. Test For Calcium:  
2ml of the extract is added with 2ml of 4% 
dil.ammonium oxalate solution  
Cloudy 
appearance and 
white precipitate  
was obtained. 
   absence   
of  Calcium 
7. Test For Magnesium:  
To 2ml of extract dil.sodium hydroxide 
solution is added in drops to excess. 
 White precipitate 
was  obtained 
 presence 
of  
Magnesium 
8. Test For Ammonium: 
  To 2ml of extract 1 ml of Nessler's reagent 
and excess of dil.sodium hydroxide solution 
are added. 
No Brown colour 
appeared 
     Absence  
 of 
Ammonium 
9. Test For Potassium:  
   A pinch (25mg) of substance is treated of 
with 2ml of dil.sodium nitrite solution and 
then treated with 2ml of dil.cobalt nitrate in 
30% dil.glacial acetic acid. 
 
No Yellowish 
precipitate was 
obtained. 
 
   Absence  
of  Potassium 
10. Test For Sodium: 
    2 pinches (50mg) of the substance is made 
into paste by using HCl and introduced into 
the blue flame of Bunsen burner. 
No Yellow 
coloured flame 
appeared 
Absence 
of  Sodium 
11. Test For Mercury:  
   2ml of the extract is treated with 2ml of 
dil.sodium hydroxide solution.  
No yellow 
precipitate was 
obtained. 
Absence of 
Mercury 
12. Test For Arsenic:  
   2ml of the extract is treated with 2ml of 
dil.sodium hydroxide solution. 
No brownish red 
precipitate was 
obtained. 
Absence 
of Arsenic 
III. MISCELLANEOUS 
1.
  
Test For Starch:  
2ml of extract is treated with weak 
dil.Iodine solution  
 
No Blue colour 
developed 
 
Absence  
of  Starch 
2.
  
Test For Reducing Sugar:  
    5ml of Benedict's qualitative solution is 
taken in a test tube and allowed to boil for 
2 minutes and added 8 to 10 drops of the 
extract and again boil it for 2 minutes. The 
colour changes are noted. 
 
 
 Brick Red colour 
developed 
 
absence of 
Reducing 
sugar. 
3.
  
Test For The Alkaloids: 
a) 2ml of the extract is treated with 2ml of 
dil.potassium lodide solution. 
b)  2ml of the extract is treated with 2ml of 
dil.picric acid. 
c)  2ml of the extract is treated with 2ml of 
dil.phosphotungstic acid. 
 
 No Red colour 
developed 
 
 
 
 
 
  abssence  
of Alkaloid 
4.
  
Test For Tannic Acid:  
  2ml of extract is treated with 2ml of 
dil.ferric chloride solution  
No black precipitate 
was obtained 
Absence of 
Tannic acid 
5.
  
Test For Unsaturated Compound: 
  To the 2ml of extract 2ml of 
dil.Potassium permanganate solution is 
added.  
Potassium 
permanganate is not 
decolourised 
Absence of 
unsaturated 
compound 
6.
  
Test For Amino Acid: 
    2 drops of the extract is placed on a 
filter paper and dried well. 20ml of  
Biurette reagent is added. 
No Violet colour 
developed 
   Absence   
of Amino 
acids 
7. Test For Type Of Compound: 
    2ml of the extract is treated with 2 ml of 
dil.ferric chloride solution.  
  
No Green colour 
developed 
 
 
 
No Red colour 
developed 
 
 
 
No Violet colour 
developed 
 
 
 
No blue colour 
 developed 
Absence of 
oxy 
quinole 
epinephrine 
and pyro 
catechol. 
Anti pyrine, 
Aliphatic          
amino acids 
and Meconic 
acid are 
absent. 
Apomorphine, 
Salicylate and 
Resorcinol are 
absent. 
Morphine, 
Phenol 
cresol and 
hydro 
quinone are 
absent 
 
 
RESULT: 
The bio-chemical analysis Gandhaga mezhugu of had shown the presence of   
Silicate, Carbonate, Chloride, Calcium, Sulphide, Sulphate, Reducing sugars and Alkaloids. 
 
 
 
 
 
Subject Selection: 
         Patients reporting with symptoms of inclusion criteria was subjected to screening test and 
documented using screening proforma 
Inclusion Criteria: 
 Age: 20 – 60 years 
 Sex: Both Male and Female 
 Clinical features like; Itching, Oozing, Erythema, Papules, Vesicles, Scaling, 
Hyperpigmentation 
 Willing to give specimen of blood for investigation when required. 
 Willing for admission and study in IPD for 10 days or willing to attend OPD 
 Willing to take photograph before and after treatment 
 
Exclusion Criteria: 
 Diabetes mellitus 
 Hypertension and other Cardiac ailments 
 Narcotic addicts 
 Pregnancy and Lactation 
 Evidence of  any skin disease other than eczema 
 Varicose eczema. 
Withdrawal Criteria: 
 Intolerance to the drug and development of adverse drug reactions during drug trial. 
 Poor patient compliance and defaulters. 
 Patient unwilling to continue in the course of clinical trial. 
 Any drastic changes occurring in haematological finding during treatment period. 
 Increased in severity of symptoms 
Tests and Assessments: 
A. Clinical assessment 
B.   Siddha system of examination 
C. Laboratory investigations 
A. Clinical Assessment: 
 Itching 
 Erythematous lesions with oedema 
 Presence of macule / Papule / Vesicle / Pustule 
 Oozing , scaling, lichenification of skin 
 Hyper / hypo depigmentation     
 Appearance of new lesions 
 Size of the lesions 
 
B.  SIDDHA SYSTEM OF EXAMINATION: 
                En Vagai Thervugal: 
                          1. Naadi. 
                          2. Sparisam  
                          3. Naa  
                          4. Niram  
                          5. Mozhi  
                          6. Vizhi  
                          7. Malam 
                          8. Moothiram - Neerkkuri 
         Neikkuri 
C. LABORATORY INVESTIGATIONS:  
Blood: 
Hb 
Total WBC Count 
DC- Polymorphs 
          Lymphocytes  
          Eosinophils  
          Monocytes  
          Basophils  
Total RBC count  
ESR 
Blood sugar (F)                   (PP) 
 
RENAL FUNCTION TESTS: 
             Urea 
             Creatinine 
             Uric acid 
 LIVER FUNCTION TESTS: 
              Serum total bilirubin 
              Direct bilirubin 
              Indirect bilirubin 
              Serum Alkaline phosphatase 
              SGOT 
              SGPT 
   LIPID PROFILE: 
   HDL:  
   LDL:               
   VLDL:  
   Total Cholesterol  
   TGL:   
URINE: 
        Albumin 
            Urine sugar- (F)                   (PP) 
            Deposits 
 
DATA COLLECTION FORMS: 
Required information will be collected from each patient by using the following forms 
Form l            : Screening Proforma  
Form lI      : Clinical Research Form  
Form llI      : Laboratory Investigation Proforma 
Form lV    : Drug compliance Form 
Form V     : Patient information Form 
Form VI     : Informed Consent Form 
Form VII     : Pharmocovigilance/Withdrawl form 
Form VIII     : Dietary advice Form  
Outcome [EASI SCORE]: 
 The outcome is mainly assessed by reduction in symptoms like itching, oozing etc. 
Improvement assessed by EASI SCORE               
Eczema Area and Severity 
Index( EASI)Score 
Before treatment After treatment 
  
EASI score 
An EASI score is a tool used to measure the severity and extent of atopic eczema 
(Eczema Area and Severity Index).  
There are four body regions: 
      1.Head and neck                              2.Upper limbs 
3.Trunk                                            4.Lower limbs 
Intensity: The intensity of rednes, thickness, scratching, lichenification  of the eczema is 
assessed as none (0), mild (1), moderate (2) and severe (3). Half scores are allowed. The four 
intensity scores are added up for each of the four body regions to give subtotals A1, A2, A3, 
A4. 
Area: The percentage area affected by eczema is evaluated in the four regions of the 
body. In each region, the area is expressed as nil (0), 1-9% (1), 10-29% (2), 30-49% (3), 50-
69% (4), 70-89% (5) or 90-100% (6). 
Caculation for area: Each of the body area scores is multiplied by the area affected 
(C1,C2,C3,C4) 
Total score: The EASI score is C1 + C2 + C3 + C4. 
 
The SCORAD index 
A = spread.../100 
B = intensity.../18 
C = subjective symptoms.../20                                                                        
SCORAD calculation: A/5 + B/2 + C 
 
 PATIENT SCREENING 
Inclusion/Exclusion 
INCLUSION CRITERIA EXCLUSION CRITERIA 
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CLINICAL ASSESSMENT 
OUTCOME 
INFORM ABOUT STUDY AND TRIAL 
DRUG 
INFORMED CONSENT FORM 
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OPD 
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 Study enrollment: 
Patients reporting at the OPD with the clinical symptoms of Karappan was examined 
clinically for enrolling in the study based on the inclusion and exclusion criteria.  
The patients who are enrolled was informed (Form-V) about the study, trial drug, possible 
outcomes and the objectives of the study in the language and terms understandable to them and the 
informed consent would be obtained in writing from them in the consent form (Form VI).  
All these patients was given unique registration card in which the patients’ Registration 
number of the study, Address, Phone number and Doctor’s phone number etc. will be given, so as to 
report easily should any complications arise. 
Complete clinical history, complaints, duration, examination findings and laboratory 
investigations -- was recorded in the prescribed Proforma. Screening Form- I will be filled up: Form –
II and Form –III was used for recording the patient’s history, clinical examination of symptoms, signs 
and laboratory investigations respectively. Patients was advised to take the trial drug and appropriate 
dietary advice was given according to the patient`s perfect understanding. 
Conduct of the Study: 
  The day before the treatment purgation with Agasthiyar Kuzhambu – 130 mg at early morning 
in empty stomach with Sangangkuppi juice will be given for balancing the deranged Uyir thathu on 
the first day of the treatment.  
 From the next day onwards, the trial drugs “Parangisakkai Chooranam ” was internally 
given continuously for 40 days and “Karappan Ennai” will be applied externally for 40 days. OPD 
patients was advised to visit the hospital once in 7 days for 40 days. At each clinical visit, clinical 
assessment is done and prognosis is noted. For 20 patients, the drug is given for 40 days along with 
Yogam.  
             Laboratory investigations are done on the first and the 40 day of the trial. After the trial 
period, the patients was advised to visit the OPD for follow-up for further two months to observe any 
recurrence. Defaulters was not allowed to continue the trial will be withdrawn from the study.  
Data Analysis: 
 After enrolling the patient in the study, a separate file was maintained for each and every 
patient and all forms and other information was kept in the file. The screening forms was filed 
separately. The data entry was monitored by the Head of the department and faculty members of dept. 
of Sirappu Maruthuvam. All collected data was statistically analysed by Sr. Research Officer 
(Statistics) for logical errors and incompleteness of data to avoid any bias. No modification in the 
results was permitted for unbiased reports. Then final report was generated. 
 
Adverse Effect/Serious Adverse Effect Management:  
 If the trial patient develops any adverse reactions, he/she would be immediately withdrawn 
from the trial, informed to the pharmacovigilance committee of NIS and referred to the concerned 
OPD of National Institute of Siddha for further management. 
Ethical Issues: 
1. To prevent any infection, while collecting blood sample from the patient, only disposable 
syringes, disposable gloves, with proper sterilization of lab equipments was used.      
2. No other external or internal medicines will be used other than the trial drug, for treating 
Karappan. There was no infringement on the rights of patient.    
3. The data collected from the patient will be kept confidential. The patient was informed about 
the diagnosis, treatment and follow-up.  
4. After the consent of the patient (through consent form) they was enrolled in the study.  
5. Informed consent was obtained from the patient explaining to him/her in the language 
understandable to the patient. 
6. Treatment was provided free of cost.  
7. In case of any serious adverse reactions, the patients was given alternative treatment at the 
National Institute of Siddha. 
 
 
 
 
 
 
 
 
 
                     OBSERVATION AND RESULTS 
 
The observation and results have been tabulated under the following headings. 
 Sex distribution 
 Age distribution 
 Kaalam distribution 
 Socio economic status 
 Occupational status 
 Family History 
 Dietary habits 
 Paruvakaalam 
 Thinai  
 Yakkai Ilakkanam (Physical Constitution) 
 Gunam  
 Duration of illness 
 Clinical features 
 Site of lesion 
 Distribution of mukkutram 
 Udar Kattugal  
 En Vagai  thervugal 
  Neikkuri  
 Statistical analysis 
 
 
1. SEX DISTRIBUTION 
 
 
 
Sl No Sex No of Cases Percentage 
1 Male 22 55% 
2 Female 18 45% 
 
 
 
  
 
 
Observation 
Among the 40 patients included in this study, 55% were male and 45% female. 
 
2. AGE DISTRIBUTION 
 
 
Sl. No Age No of Cases Percentage 
1 20-30 4 10% 
2 31-40 8 20% 
3 41-50 17 42.5% 
4 51-60 11 27.5% 
                                                           
 
 
Male 
55% 
Female 
45% 
SEX 
  AGE DISTRIBUTION 
 
 
Observation 
 
  Among the 40 patients selected for this study, maximum numbers of patients 42.5% 
were in the age group of 41 to 50yrs, 27.5% were in the age group of 51 to 60yrs, 20% were 
in the age 31 to 40yrs and 10%  were in the age of 20 to 30yrs. 
 
3.AYUL  KAALAM DISTRIBUTION (According to Age) 
 
In Siddha literature human life has been divided into three periods as follows 
1 Vaatha kaalam 
2 Pitha kaalam 
3 Kaba kaalam 
The duration of each period is said to be 33 years 
Sl No Kaalam No of Cases Percentage 
1 Vatha Kaalam (1-33 Years) 5 12.5% 
2 Pitha  Kaalam (34-66 years) 35 87.5% 
3 Kaba Kaalam (67-100 years) 0 0% 
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80.00%
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 KAALAM DISTRIBUTION 
 
 
Observation 
 
Out of 40 patients, 35 patients were reported in Pitha kaalam, the remaining 5 in 
Vatha kaalam. 
 
4.SOCIO ECONOMIC STATUS 
 
Sl. No 
ECONOMIC STATUS 
 
No of Cases Percentage 
1 Low income  19 47.5% 
2 Middle income 14 35% 
3 High income 7       17.5% 
 
0%
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Observation 
                Out of 40 patients, 47.5% patients were under low income group, 35% patients 
were middle income group,  the remaining 17.5% patients were under high income group. 
5. OCCUPATIONAL STATUS 
 
Sl. No Nature of Work No. of Cases Percentage 
1 Bank Employee 1 
2.5 % 
2 House keeping 2 
5% 
3 Business 4 10 % 
4 Home Maker 11 27.5 % 
5 Coolie 3 7.5% 
6 Building work 4 10 % 
7 Security 3 7.5% 
8 Teacher 2 5 % 
9 Leather factory 1 2.5 % 
10 IT professional 1 2.5% 
11 Driver 2 5 % 
12 Mechanic 2 5% 
47.5% 
35% 
17.5% 
low income
middle income
high income
13 Power plant 3 7.5% 
14 Hair stylist 1 2.5% 
 
 
 
Observation 
Among 40 patients 27.5% cases were home makers, 10%  were at building work, 10% 
patients were in business , 7.5% of them were coolie, security, powerplant employee, 5% 
were house keeping, mechanic, driver, teacher, ,2.5% of them were leather factory 
employee,bank employee, hair stylist, IT proffessional. 
6. FAMILY HISTORY 
Sl. No 
 
Criteria 
 
No of Cases Percentage 
1 
 
Family History (+ve) 
 
3 7.5% 
2 
 
Family History (-ve) 
 
37 92.5% 
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Observation 
 
 Among 40 patients , 92.5% of the patients showed no family history, 7.5% showed 
positive family history. 
 
 
 
7.  DIETARY HABITS 
 
Sl. No Dietary Habits No of Cases Percentage 
1 Vegetarian 4 10% 
2 Non Vegetarian 36 90% 
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Observation 
90% cases are non-vegetarian. 
 
8. PARUVA KAALAM 
 
Sl 
No. 
Paruva Kaalam No. of Cases Percentage 
1 Kaar kaalam (Aavani & Purattasi) 0 0 
2 Koothir Kaalam (Aippasi&Kaarthigai) 1 2.5% 
3 Munpani Kaalam (Margazhi& Thai) 31 77.5% 
4 Pinpani Kaalam (Maasi&Panguni) 8 20% 
5 Elavenil Kaalam (Chithirai & Vaikasi) 0 0 
6 Muthuvenil Kaalam (Aani&Aadi) 0 0 
 
10.00% 
90.00% 
DIETARY HABIT 
Vegetarian
NON Vegetarian
 
 
Observation 
Among the 40 patients admitted for this study, the highest number of patients(77.5%) 
reported in Munpani Kaalam, 20% are reported in Pinpani Kaalam and 2.5% are reported in 
koothir kaalam. 
9. THINAI REFERENCE 
 
Sl. No Thinai No. of Cases Percentage 
1 Kurinji (Hill Area) 3 7.5% 
2 Mullai (Forest Area) 0 0 
3 Marutham (Fertile Land) 1 2.5% 
4 Neithal (Coastal Area) 36 90% 
5 Palai (Desert Land) 0 0 
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Observation 
Among the 40 patients, 90% of the patients were from Neithal (Coastal Area), 7.5% 
were from Kurinji(hill area) and the remaining 2.5% are from Marutham (Fertile Land). 
10. YAAKAI ILAKKANAM 
 
Sl. No Yaakai Ilakkanam No. of Cases Percentage 
1 VathaUdal 0 0% 
2 PithaUdal 0 0% 
3 KabaUdal 0 0.00% 
4 ThonthaUdal 40 100% 
 
Observation 
In 40 patients 100% had Thontha Udal 
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11. GUNAM (QUALITY AND CHARACTERS) 
 
Sl. No Gunam No of Cases Percentage 
1 Satthuva Gunam 0 0% 
2 Raso Gunam 40 100% 
3 Thamo Gunam 0 0% 
 
Observation 
In 40 patients 17.5%  of them had sathuva gunam 62.5% patients had rasogunam and  
20% had Thamo gunam. 
 
12. DURATION OF ILLNESS 
 
 
Sl. No Duration of Illness No of Cases Percentage 
1 > 1 Year 12 
30% 
2 1-5 Years 13 
32.5 % 
3 6-10 Years 9 
22.5 % 
4 11-15 Years 2 
5% 
5 16-20 Years 4 
10% 
 
 Observation:   
 
Among the 40 patients the maximum number of patients (32.5%) had the duration of 
illness between 1-5 years , 30% of them had  > 1 Year, 22.5% were  6-10 yrs, 10% were <15 
yrs, 5% were 11-15 yrs. 
 
13. CLINICAL FEATURES 
 
Sl. 
N
o 
Clinical Features 
No of Cases Percentage 
BT AT BT AT 
1 Itching 40 4 100% 
10% 
2 Vesicle formation 11 0 27.5% 
0% 
3 Oozing 38 2 95% 
5% 
4 Papules 35 2 87.5% 
5% 
5 Scaling 4 1 10% 
2.5% 
6 Erythema 16 4 40% 
10% 
7 Hyperpigmentation 40 40 100% 
100% 
8 Hypopigmentation 5 5 12.5% 
12.5% 
9 Lichenification 10 2 17.5% 
5% 
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Observation:   
                  Among 40 patients included in the study, before treatment 100% of cases suffered 
from  itching and hyperpigmentation , 95% of them had oozing , 87.5% of them had papules, 
40% of them had erythema, 27.5% of them had vesicles 17.5% of them had lichenification, 
12.5%  of them had hypopigmentation and 10% of them had scaling, after treatment 10% of 
cases had itching, 100% of them had   hyper pigmentation,5% of them had oozing , 5% of 
them had papules, 10% of them had erythema, none of them had vesicles, 5% of them had 
lichenification, 12.5%  of them had hypopigmentation and 2.5% of them had scaling. 
 
14. SITE OF LESION 
Sl. No                Site of Lesion No of Cases          Percentage 
   1  Both Upper Limb               0            0% 
   2  Both  Lower Limb              20            50% 
   3  Upper limb & Lower limb              18              45% 
   4  Upper limb, Lowerlimb, Trunk 
and face 
             2              5% 
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Observation 
         Among 40 patients 60% had the lesion in  both lower limb, 35% had the lesion both in 
upper limb and in lower limb and 7.5% had Upper limb, Lowerlimb, Trunk and face  
15.DISTRIBUTION OF UYIRTHATHUKKAL 
The derangement of Vaatham, Pitham and Kabam in Karappan is as follows 
 
VAATHAM 
 
Sl. No Classification of Vaatham No of Cases Percentage 
1 Praanan 0 0% 
2 Abaanan 7 17.5% 
3 Udhaanan 0 0% 
4 Samaanan 40 100% 
5 Viyaanan 40 100% 
6 Naagan 0 0% 
7 Koorman 0 0% 
8 Kirukaran 0 0% 
9 Devathathan 8 20% 
10 Dananjayan 0 0% 
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Observation  
Samanan and Viyanan (itching present)  was found to be affected in all the 40 patients 
and devathathan (sleep disturbances) was affected in 20% of patients, Abanan was affected in 
17.5%  of  patients (had constipation). 
PITHAM 
 
Sl. 
No 
Classification of Pitham No. of Cases Percentage 
1 Akkanal (Anarpitham) 0 0% 
2 Vanna Eri (Ranjakam) 3 7.5% 
3 Atralangi (Sathakam) 3 7.5% 
4 Nokkanal (Alosakam) 0 0.00% 
5  Ullolli thee (Prasakam) 40 100.00% 
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Observation 
Prasakam was affected in all the cases. Vanna Eri (anaemia) was affected in 7.5% of 
patients and Atralangi (movement restrictions present) was affected in 7.5% of patients. 
KABAM 
 
Sl. No Classification of Kabam No of Cases Percentage 
1 Avalambagam 0 0.00% 
2 Kilethagam 4 10% 
3 Pothagam 0 0.00% 
4 Tharpagam 0 0.00% 
5 Santhigam 3 7.5% 
 
 
0%
20%
40%
60%
80%
100%
0% 
7.5% 7.5% 
0% 
100% 
PITHAM 
  
 Observation  
In 10 % of the patients, Kilethagam (indigestion)was found to be affected. Santhigam 
(movement restrictions present in joints)  was affected in 7.5% of the patients. 
16. UDAL KATTUKAL 
 
 
Sl. No UdarKattugal No of Cases Percentage 
1 Saaram 40 100% 
2 Senneer 40 100% 
3 Oon 40 100% 
4 Kozhuppu 0 0% 
5 Enbu 0 0% 
6 Moolai 0 0% 
7 Sukkilam/Suronitham 0 0 % 
  
Observation: 
Among 40 patients, Saaram, Senneer , Oon were affected in all the cases. 
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17. EN VAGAI THERVUKAL 
 
Sl. 
No 
En VagaiThervukal No. of Cases Percentage 
1 Naa 0 0% 
2 Niram 40 100% 
3 Mozhi 0 0% 
4 Vizhi 0 0% 
5 Sparisam 40 100% 
6 Malam 7 17.5% 
7 Moothiram 0 0% 
8 Naadi   
 a. Vathapitham 25 62.5% 
 b. Pithavatham 15 37.5% 
 
Observation: 
In Envagaithervukal, Niram and Sparisam were found to be affected in all the 40 
cases. The Naadinadai seen in  Karappan patients were Vathapitham 62.5 %, Pithavatham 
37.5 %. 
18. NEERKKURI, NEIKKURI REFERENCE  
 
Sl. 
No 
Type of Test No. of Cases Percentage 
 
                          Neikkuri 
1  Vaatha neer –‘Aravena neendin’ 3 7.5% 
2  Pitha neer-‘Aazhi pol paravin’ 3 7.5% 
3  Kaba neer – ‘Muththothu Nitral’ 34 85% 
 
 Observation: 
              In Neikkuri Vatha neer was found in 7.5% patients, Pitha neer was found in  7.5% 
patients and Kaba neer was  found in 85% patients. 
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PATIENT’S BLOOD INVESTIGATION CHART   
 
 
Sl.no Op .no 
Hb gm% TC Cells/Cumm 
RBC 10
6
 
Cells/cu.mm 
ESR/hr 
BT AT BT AT BT AT BT AT 
1 
I53173 10.3 11.1 6700 8100 4.4 4.7 50/40 10/34 
2 
J74566 14.2 14.0 9700 8600 4.3 4.2 8/16 4/10 
3 
J71057 12.2 12 5600 6000 4.2 4.3 2/2 6/4 
4 
J27416 12.4 11.6 6300 6600 4.9 4.6 6/10 8/16 
5 
J61604 13.9 13.4 10300 9700 5.1 4.9 6/14 24/50 
6 
J64132 13.5 13.6 5600 5800 5.6 4.4 10/24 12/16 
7 
J83804 13.3 13.0 7100 7700 4.8 4.8 14/30 12/28 
8 
J88835 11.9 12 8800 8000 4.6 4.2 16/34 10/24 
9 
I38346 12.4 12 8500 8600 4.8 4.8 8/16 10/14 
10 
K04479 12.3 12.5 8000 8100 4.4 4.5 40/82 20/28 
11 
J11986 11.2 11 7200 7600 5.0 4.9 12/24 14/20 
12 
G29270 12.9 14.1 8500 7600 4.0 4.7 26/54 12/28 
13 
J86172 12.3 12.4 9700 9700 4.6 4.6 10/12 12/16 
14 
G14967 11.9 12.1 8100 12300 4.2 4.2 20/42 10/42 
15 
F77246 16.8 16.6 8500 8800 5.7 5.6 8/16 10/20 
16 
J96575 15.1 15.3 8700 7700 5 5.3 2/6 2/8 
17 
J81340 9.7 10 8100 8200 4.3 4.2 22/46 20/40 
18 
J85942 12.9 13.0 8800 8600 4.7 4.6 30/62 10/20 
19 
J97372 14.7 15.0 6700 8500 4.2 4.1 12/26 10/18 
  20 
J86723 13.9 13.5 7400 7200 4.5 4.4 4/10 2/8 
 
 
 
 
 
  
 
 
PATIENT’S   BLOOD   INVESTIGATION   CHART 
 
 
Sl.no 
Op .no 
Poly 
morphs 
Lymphocytes Mono 
Cytes 
Eosino 
phils 
 BT AT BT AT BT AT BT AT 
1 I53173 61 64 34 34 05 02 03 04 
2 J74560 65 68 30 29 05 05 3 03 
3 J71057 65 63 22 20 4 4 3 5 
4 J27416 60 66 35 29 04 05 1 4 
5 J61604 78 77 19 20 5 5 3 3 
6 J64132 70 69 25 26 4 4 3 4 
7 J83804 62 70 35 27 6 5 3 3 
8 J88835 70 65 28 25 5 5 2 2 
9 J38346 75 73 23 25 8 6 2 2 
10 K04479 66 65 32 30 4 5 2 2 
11 J11986 68 70 27 30 2 4 3 3 
12 G29270 66 64 32 33 4 1 2 3 
13 J86172 74 72 24 25 4 4 2 1 
14 G14967 66 78 30 19 4 5 2 3 
15 F77246 67 65 28 30 2 2 3 3 
16 J96575 79 76 17 21 5 5 4 3 
17 J81340 76 70 22 25 4 4 2 3 
18 J85942 66 68 32 35 4 4 2 2 
19 J97372 66 65 31 31 1 2 2 4 
20 J86723 70 70 25 26 4 4 2 2 
 
  
 
 
 
PATIENT’S   BLOOD   INVESTIGATION   CHART 
 
 
Sl.no 
Op .no Blood Sugar(F) Blood Sugar(PP) 
 BT AT BT AT 
1 
J53173 97  124 132 
2 
J74560 86 98 105 120 
3 
J71057 83 89 103 108 
4 
J27416 83 86 106 110 
5 
J61604 102 102 148 145 
6 
J64132 90 98 120 126 
7 
J83804 103 112 114 151 
8 
J88835 80 86 110 105 
9 
I38346 88 90 143 148 
10 
K04479 84 86 115 110 
11 
J11986 93 90 70 100 
12 
G29270 96 90 120 112 
13 
J86172 93 96 126 127 
14 
G14967 103 106 131 171 
15 
F77246 87 87 105 110 
16 
J96575 87 88 117 120 
17 
J81340 106 109 141 126 
18 
J85942 113 110 122 129 
19 
J97372 106 114 117 115 
20 
J86723 98 90 115 120 
  
 
OUT-PATIENT’S   RENAL FUNCTION TEST CHART 
 
 
 
Sl.no Op .no 
Urea 
mg/dl 
 
Creatinine 
mg/dl 
 
Uric Acid 
mg/dl 
BT AT BT AT BT AT 
1 
I53173 17 21 0.8 0.9 4.2 3.7 
2 
J74560 18 11 1.6 1.2   
3 
J71057 20 24 0.9 0.9 6.4 6.0 
4 
J27416 14 11 1.0 0.8 3.3 3.4 
5 
J61604 15 16 0.9 1.0 4 3.6 
6 
J64132 20 24 0.8 0.9 4 4.6 
7 
J83804 17 19 0.9 1.0 4.6 4.3 
8 
J88835 21 24 0.8 0.8 4 4.2 
9 
I38346 19 22 0.8 1.0 5.8 5.6 
10 
K04479 16 18 1.0 0.9 5.0 5.2 
11 
J11986 15 20 1.0 1.0 6 6.2 
12 
G29270 18 18 0.9 1.1 6.0 6.0 
13 
J86172 15 15 0.8 0.9 6.0 4.9 
14 
G14967 18 18 0.7 0.7 4.2 3.2 
15 
F77246 11 18 1.1 1.0 4.8 4.8 
16 
J96575 23 25 1.0 1.0 6 6 
17 
J81340 19 20 0.9 0.8 4.9 4.6 
18 
J85942 14 20 0.8 0.8 5.1 5.0 
19 
J97372 22 26 1.0 1.2 6.2 6.9 
20 
J86723 24 23 1.1 1.1 6.3 6.2 
  
PATIENT’S  LIVER FUNCTION TEST CHART 
 
 
 
Sl.no 
Op .no 
Total 
Bilirubin 
mg/dl 
Direct 
Bilirubin 
mg/dl 
Indirect 
Bilirubin 
mg/dl 
SGOT 
IU 
SGPT 
IU 
Alk.phos 
mg/dl 
 BT AT BT AT BT AT BT AT BT AT BT AT 
1 I53173 0.6 0.6 0.2 0.2 0.4 0.4 14 10 12 14 71 60 
2 J74566 0.7 0.5 0.3 0.2 0.4 0.3 23 21 16 20 76 77 
3 J71057 0.5 0.6 0.2 0.2 0.3 0.4 14 16 18 20 84 100 
4 J27416 0.4 0.2 0.2 0.2 0.2 0.6 08 08 11 16 69 100 
5 J61604 0.7 0.6 0.3 0.2 0.4 0.4 12 13 11 11 89 90 
6 J64132 0.3 0.3 0.2 0.2 0.3 0.3 16 18 20 20 69 80 
7 J83804 0.3 0.5 0.1 0.2 0.2 0.3 11 11 14 13 66 69 
8 J88835 0.4 0.4 0.2 0.2 0.2 0.2 18 20 19 25 92 100 
9 I38346 0.5 0.6 0.2 0.2 0.3 0.3 21 20 14 16 77 80 
10 K04479 0.5 0.5 0.2 0.3 0.3 0.2 16 20 23 25 64 80 
11 J11986 0.4 0.5 0.2 0.2 0.2 0.2 12 12 21 20 116 120 
12 G29270 0.3 0.5 0.1 0.2 0.2 0.3 15 19 21 29 125 111 
13 J86172 0.7 0.7 0.3 0.2 0.4 0.5 12 11 09 0.5 67 66 
14 G14967 0.2 0.4 0.1 0.2 0.1 0.4 14 12 22 11 107 82 
15 F77246 1.2 1.0 0.4 0.4 0.8 0.6 25 25 28 30 51 60 
16 J96575 0.4 0.4 0.2 0.3 0.3 0.3 18 22 22 18 59 70 
17 J81340 0.5 0.6 0.2 0.2 0.3 0.3 27 30 24 28 64 80 
18 J85972 0.6 0.5 0.2 0.3 0.4 0.4 14 20 21 25 77 90 
19 J97372 0.5 0.7 0.2 0.2 0.3 0.5 17 17 22 15 47 50 
20 J86723 0.5 0.5 0.2 0.3 0.3 0.2 15 20 18 24 83 90 
 
PATIENT’S URINE INVESTIGATION CHART 
 
 
 
S.no Op.no 
Albumin Sugar Deposits 
BT AT BT AT BT AT 
 
1 
I53173 Nil Nil Nil Nil 1-2Pus  1-4Pus , 4-6 Epi 
2 
J74566 Nil Nil Nil Nil 1-2Pus, 2-3 Epi 2-4Pus,2-4 Epi 
3 J71057 
Nil Nil Nil Nil 1-3Pus, 2-3 Epi 1-2Pus, 1-3 Epi 
4 
J27146 Nil Nil Nil Nil 2-3Pus, 1-2 Epi 1-2Pus, 1-2 Epi 
5 J61604 
Nil Nil Nil Nil 1-2Pus,1-2Epi 1-2Pus, 1-2 Epi 
6 
J64132 Nil Nil Nil Nil 1-2Pus, 2-3 Epi 1-2Pus, 2-3 Epi 
7 
J83804 Nil Nil Nil Nil 2-4Pus, 4-6Epi 2-4Pus, 2-4 Epi 
8 
J88835 Nil Nil Nil Nil 1-3Pus, 2-3 Epi 1-3Pus, 2-3 Epi 
9 
I38346 Nil Nil Nil Nil 1-2Pus, 3-5 Epi 1-2Pus, 3-5 Epi 
10 
K04479 Nil Nil Nil Nil 1-3Pus, 2-3 Epi 1-3Pus, 2-3 Epi 
11 
J11986 Nil Nil Nil Nil 1-2Pus, 2-3 Epi 1-2Pus,2-3 Epi 
12 G29270 
Nil Nil Nil Nil 3-5Pus, 1-2 Epi 1-2Pus, 1-2 Epi 
13 
J86172 Nil Nil Nil Nil 3-5Pus, 1-2Epi 3-4 Pus, 1-2 Epi 
14 
G14967 Nil Nil Nil Nil 3-5Pus, 1-2Epi 10-12Pus, 6-8 Epi 
15 
F77246 Nil Nil Nil Nil 1-2Pus, 1-2Epi 1-2Pus, 2-3 Epi 
16 J96575 
Nil Nil Nil Nil 2-4 Pus,2-6 Epi 4-6 Pus, 4-6 Epi 
17 
J81340 Nil Nil Nil Nil 4-5 Pus 1-2Epi 2-3 Pus, 1-2Epi 
18 
J85942 Nil Nil Nil Nil 1-3 Pus,1-3 Epi 1-3Pus, 2-3 Epi 
19 
J97372 Nil Nil Nil Nil 1-2Pus, 1-2 Epi 3-4Pus, 1-2 Epi 
20 
J86723 Nil Nil Nil Nil 4-6Pus, 1-2 Epi 1-2Pus, .2-4 Epi 
 
 
 
PATIENT’S   BLOOD   INVESTIGATION   CHART 
  
Sl.no 
IP .No 
Hb 
gm% 
TC 
Cells/ 
Cu.mm 
RBC 
million 
Cells/ 
cu.mm 
ESR 
 (mm/hr) 
 BT AT BT AT BT AT BT AT 
1 K6028 14.7 14.6 8600 8600 5.1 5 12/24 10/12 
2 J12564 11.9 11.8 7800 7800 4.5 4.6 10/16 12/26 
3 J97100 12.7 12.2 5900 6700 4.8 4.6 6/12 10/20 
4 F97306 13.7 13.5 6700 6700 4.5 4.5 20/40 20/42 
5 I65375 12.2. 12 9300 8000 6 5.8 16/34 12/26 
6 F87188 13.7 13.6 5600 6000 4.8 4.7 2/10 2/6 
7 J39085 13.7 13.9 8800 8900 4.6 4.7 4/16 20/42 
8 E18015 11.1 12 10300 9300 4.6 4.6 2/8 2/10 
9 J86790 14.1 14 7700 7800 4.6 4.6 12/26 12/30 
10 K16565 15.3 15 10000 9000 5 5.1 10/30 6/12 
11 J83153 14.5 14.5 8000 7900 5.5 5.4 2/10 2/8 
12 I59680 14.2 14.2 7300 7600 4.9 4.8 16/34 16/32 
13 K18519 15.6 16 9300 9000 5.4 5.4 10/20 12/18 
14 J70192 12.6 12.9 6600 6600 4.6 4.8 22/46 10/20 
15 G92688 13 12.9 6000 6900 4.8 4.7 10/18 12/16 
16 J48553 12.6 11.6 6100 8700 4.4 4.1 20/40 32/64 
17 H93183 15.7 15.5 9500 9800 5.2 5.2 2/10 2/10 
18 J85942 13 12.7 7300 7000 4.5 4.7 4/12 4/8 
19 K04479 11.2 10.9 8900 6900 4.6 4.7 24/48 20/40 
20 J51869 11.7 11.2 8900 7900 5.2 4.9 2/6 2/4 
 
 
 
 
  
PATIENT’S   BLOOD   INVESTIGATION   CHART 
 
 
Sl.no Ip .no 
Poly 
morphs 
Lymphocytes Mono 
Cytes 
Eosino 
Phils 
BT AT BT AT BT AT BT AT 
1 K6028 63 65 34 30 6 7 3 4 
2 J12567 60 64 30 33 5 5 3 3 
3 J97100 66 75 27 20 8 5 2 4 
4 F92306 71 60 26 20 5 6 3 3 
5 I65375 60 61 35 33 2 6 3 2 
6 F87188 54 56 24 28 6 6 2 1 
7 J39085 75 68 22 27 4 5 3 2 
8 E18015 70 70 28 30 4 5 2 2 
9 J86790 61 65 33 30 2 2 4 4 
10 K16565 76 74 20 22 4 4 4 4 
11 J83153 67 65 31 25 4 4 2 2 
12 I59680 59 60 37 40 1 1 3 3 
13 K18519 65 68 31 32 1 1 3 3 
14 J70192 64 60 30 33 6 7 2 4 
15 G92688 77 75 18 22 1 2 4 3 
16 H93183 72 70 23 25 5 5 2 2 
17 J51869 53 59 43 37 4 3 2 4 
18 J85942 47 45 44 40 1 1 2 3 
19 K04479 56 55 40 35 5 4 3 2 
20 J51869 65 63 30 32 5 4 3 3 
 
PATIENT’S   BLOOD   INVESTIGATION   CHART 
 
 
Sl.no Ip .no 
Blood Sugar(F) Blood Sugar(PP/R) 
BT AT BT AT 
1        K6028 85 90 97 102 
2 J12567 95 96 120 105 
3 J97100 83 85 132 116 
4          F92306 95 90 115 110 
5 I65375 84 86 111 96 
6 F87188 98 96 86 100 
7 J39085 85 79 101 110 
8 E18015 113 120 111 125 
9 J86790 109 110 122 124 
10 K16565 80 95 115 120 
11 J83153 106 109 110 120 
12 I59680 108 109 119 112 
13 K18519 80 88 110 118 
14 J70192 103 99 121 130 
15 G92688 93 110 96 112 
16 H93183 90 96 110 106 
17 J51869 98 96 99 100 
18 J85942 94 84 106 127 
19 K04479 100 103 142 123 
20 J51869 81 126 132 116 
 
 
 
PATIENT’S  RENAL FUNCTION TEST CHART 
 
 
 
Sl.no 
 
Ip .no 
 
Urea 
mg/dl 
 
Creatinine 
mg/dl 
 
Uric Acid 
mg/dl 
BT AT BT AT BT AT 
1 K6028 14 15 1 0.9 4.4 4.6 
2 J12564 21 25 0.9 1 4.9 4.8 
3 J97100 19 19 0.8 0.6 3.6 5.2 
4 F92306 20 24 0.9 1 4.5 5 
5 I65375 14 17 1.0 1.2 6.5 8.1 
6 F87188 23 25 1.0 1.0 3.3 3.3 
7 J39085 14 19 0.9 0.8 5.3 3.6 
8 E18015 27 30 0.9 0.6 4.9 4.6 
9 J86790 17 18 1 1 6.7 6 
10 K16565 15 19 0.8 0.8 3.7 4.2 
11 J83153 18 17 1.0 1.1 4.6 4.6 
12 I59680 19 19 1.0 1.1 8 8 
13 K18519 20 24 0.1 0.1 6 6.6 
14 J70192 15 14 0.7 0.7 3.3 3 
15 G92688 21 19 1.1 1.1 8.0 7.8 
16 H93183 19 20 1.1 1.0 8.5 8 
17 J51869 14 10 0.8 1.0 6.0 4.0 
18 J85942 34 19 0.9 0.8 5.9 5.2 
19 K04479 14 14 0.7 0.7 3.9 5.1 
20 J51869 19 24 0.7 0.6 6.2 5.9 
 
 
 
PATIENT’S  LIVER FUNCTION TEST CHART 
 
 
 
Sl.no 
 
Ip .no 
 
 
Total 
Bilirubin 
mg/dl 
 
Direct 
Bilirubin 
mg/dl 
 
 
Indirect 
Bilirubin 
mg/dl 
 
 
SGOT 
IU 
 
SGPT 
IU 
 
Alk.phos 
mg/dl 
 
  BT AT BT AT BT AT BT AT BT AT BT AT 
1 E18015 0.3 0.4 0.1 0.2 0.2 0.1 17 20 20 22 68 78 
2 J51869 0.2 0.3 0.1 0.1 0.2 0.2 26 19 32 21 87 75 
3 K4479 0.5 0.5 0.2 0.3 0.3 0.2 16 20 23 25 64 80 
4 I65375 0.2 0.5 0.3 0.2 0.3 0.2 10 15 15 13 86 87 
5 F92306 0.6 0.5 0.2 0.2 0.4 0.3 21 25 16 20 123 150 
6 J12564 0.3 0.4 0.1 0.2 0.2 0.3 15 20 17 18 94 108 
7 F87188 0.6 0.5 0.3 0.3 0.4 0.3 21 25 19 09 71 76 
8 J97100 0.3 0.2 0.5 0.5 0.2 0.4 25 20 16 22 89 110 
9 J70192 0.3 0.4 0.4 0.4 0.5 0.5 20 16 22 18 96 178 
10 H93183 0.3 0.3 0.3 0.3 0.5 0.6 20 24 16 20 89 100 
11 G92688 0.3 8 0.1 0.3 0.2 0.5 24 22 29 27 161 113 
12 K18519 0.3 0.3 0.3 0.3 0.4 0.3 20 24 24 24 90 98 
13 J83153 0.4 0.8 0.2 0.3 0.3 0.5 28 27 36 40 90 73 
14 J86790 0.7 0.6 0.2 0.2 0.5 0.3 14 15 13 20 72 80 
15 G92688 0.7 0.6 0.5 0.2 0.2 0.4 32 19 18 23 158 106 
16 H93183 0.9 0.7 0.4 0.2 0.5 0.5 12 19 14 23 80 83 
17 J51869 0.7 0.7 0.2 0.2 0.5 0.5 25 32 27 28 119 86 
18 J85942 0.5 0.7 0.2 0.3 0.3 0.4 21 15 25 18 102 79 
19 K04479 0.6 1 0.2 0.3 0.4 0.7 19 23 12 24 82 76 
20 J51869 0.7 0.7 0.3 0.4 0.4 0.3 36 29 30 31 102 107 
 
 
  
PATIENT’S   URINE   INVESTIGATION   CHART 
 
Sl.no Ip .no Albumin Sugar Deposits 
  BT AT BT AT BT AT 
1 E18015 Nil Nil Nil Nil 3-4Pus,1-2Epi 1-2Pus, 2-3Epi 
2 J51869 Nil Nil Nil Nil 1-2Pus,1-2Epi 2-4Pus, 2-4Epi 
3 K4479 Nil Nil Nil Nil 1-3 Pus, 2-3 Epi 1-3 Pus, 2-3Epi 
4 I65375 Nil Nil Nil Nil 1-2Pus, 1-2 Epi 2-4Pus, 2-4 Epi 
5 F92306 Nil Nil Nil Nil 1-2Pus, 1-2 Epi 1-2Pus, 2-3 Epi 
6 F87188 Nil Nil Nil Nil 2-4Pus, 2-4 Epi 2-4Pus, 2-5 Epi 
7 J39085 Nil Nil Nil Nil 4-5Pus, 4-5Epi 2-4Pus, 2-4 Epi 
8 J97100 Nil Nil Nil Nil 1-2Pus, 2-3 Epi 1-2Pus 2-3 Epi 
9 J70192 Nil Nil Nil Nil 1-2Pus, 2-3 Epi 1-2Pus, 2-3 Epi 
10 H93183 Nil Nil Nil Nil 2-4Pus, 1-2Epi 2-4Pus, 1-2Epi 
11 G92688 Nil Nil Nil Nil 2-4Pus, 2-4 Epi 2-4Pus,2-4Epi 
12 K18519 Nil Nil Nil Nil 1-2Pus,1-2Epi 1-2Pus,1-2Epi 
13 I59680 Nil Nil Nil Nil 2-3Pus,2-3Epi 2-3Pus,1-2Epi 
14 J83153 Nil Nil Nil Nil 1-3Pus,1-3Epi 1-3Pus,2-3Epi 
15 K16575 Nil Nil Nil NiL 1-3Pus,1-3Epi 2-3Pus, 1-2 Epi 
16 J86790 Nil Nil Nil Nil 1-2pus, 2-3 Epi 1-2Pus, 2-3 Epi 
17 J51869 Nil Nil Nil Nil 2-4Pus, 2-4Epi 2-4Pus, 2-4Epi 
18 J85942 Nil Nil Nil Nil 1-2Pus, 1-2 Epi 3-5Pus, 1-2 Epi 
19 K04479 Nil Nil Nil Nil 3-4Pus, 3-4 Epi 1-2Pus, 1-2 Epi 
20 J51869 Nil Nil Nil Nil 1-2Pus, 1-2 Epi 1-2Pus, 1-2 Epi 
 
 
 
  
 
 
 
RESULTS AND STATISTICAL ANALYSIS 
Yogam  treatment along with the trial drug: 
All collected data were entered into MS Excel software using different columns as 
variables and rows as patients. SPSS software was used to perform statistical analysis. Basic 
descriptive statistics include frequency distributions and cross-tabulations were performed. 
The quantity variables were expressed as Mean ± Standard Deviation and qualitative data as 
percentage. A probability value of <0.0001 was considered to indicate as statistical 
significance. Paired ‘t’ test was performed for determining the significance between before 
and after treatment. 
Sl. no Op .no 
Age/ 
Sex DOI 
Date Of 
Admission No of 
Days 
Treated 
EASI     Score 
 
GRADE 
BT AT 
1 0561 53/m 5yrs 10/04/18 40 39.3 6.0 EASI 75 
2 0341 59/M 5yr 28/02/17 40 
43.6 5.0 EASI 75 
3 K04479 27/F 7yrs 07/04/18 40 20 2.4 EASI 75 
4 F92306 45/F 6yrs 03/04/18 40 16.0 4.0 EASI 75 
5 K18519 33/M 2yrs 14/04/18 40 32.0 4.8 EASI75 
6 H93183 34/m 6yrs 16/04/18 40 24.0 3.6 EASI 75  
7 J27416 38/F 1yrs 11/10/18 40 8.4 0.8 EASI 75 
8 J11986 32/F    5yrs 27/12/17 40 36 12.8 EASI 75 
9 J85942 32/F 3yr 8/3/18 40 24 4.8 EASI 75 
10 J81340 30/F 4yrs 6/3/18 40 7.2 3.2 EASI 50 
11 G29270 54/F 5yrs 16/2/18 40 9.6 8.4 EASI 25 
12 G14967 29/F 10yr 19/2/18 40 9.6 2.4 EASI 50 
13 J88835 52/F 15yrs 29/1/18 40 14 6 EASI 50 
14 J61604 58/F 6yrs 26/1/18 40 28.8 3.2 EASI 75 
15 J86790 57/M 1yrs 11/4/18 40 9.6 1.6 EASI  50  
16 F87188 53/M 4yrs 9/4/18 40 16 4 EASI 75 
17 J71057 37/M 3yrs 22/12/18 40 41.4 14.6 EASI 75 
18 I53173 42/M 5yrs 10/1/18 40 33 9.9 EASI 75 
19 J51869 44/F 4yrs 10/4/18 40 16 2.4 EASI 75 
20 J48553 31/M 6yrs 15/4/18 40 16.0 8.0 EASI 50 
    
Statistical analysis for yogam with trail drugs: 
 
 
 
The mean value of  EASI score  for  patients with yogam is 13.39 and after treatment 
is 5.73. The p-value is less than 0.0001 which is significant. The reduction in the Mean was 
57.2%. Hence this study reveals Yogam treatment along with trial medicines is to be effective 
in reducing the symptoms of  Karappan.  
TRIAL DRUG MEDICINE:  
Sl. No OP .no 
Age/ 
Sex DOI 
No of 
Days 
Treated 
Date Of 
Admission 
EASI     Score 
 
GRADE 
BT AT 
1 I65375 27/M 1yrs 40 07/4/18 7.2 7.2 EASI 0 
2 J12564 52/F 8yrs 40 20/3/18 8.0 8.0 EASI 0 
3 J86723 47/M 7yrs 40 08/03/18 3.6 3.6 EASI 0 
4 K06028 40/M 2yrs 40 18/3/18 19.2 6.4 EASI 50 
5 J83153 29/M 6yr 40 12/4/18 16 2.4 EASI 75 
6 G92688 33/M 1yrs 40 15/4/18 9.6 3.6 EASI 50 
7 K16575 49/F 2yrs 40 11/4/18 22 6.4 EASI 75 
8 J70192 48/M 4yr 40 15/4/18 28.4 11.8 EASI 50 
9 I59680 44/M 6yrs 40 12/4/18 8 6.4 EASI 25 
EASI score Mean± Std p –value 
Before treatment 13.39±7.20 p<0.0001 
After  treatment 5.73± 2.59 
10 J64132 
28/M 6yrs 40 27/1/18 
10.8   3.6 
EASI 50 
  11 J83804 37/F 10yrs 40 27/1/18 18 2.4 EASI 75 
12 I38346 45/F 2yr 40 12/2/18 22   4.8 EASI 75 
13 J86172 34/F 4yrs 40 19/2/18 24 6.4 EASI 75 
14 J97100 33/M 8yrs 40 30/3/18 17.6 3.2 EASI 75 
15 F77246 28/M 1yrs 40 25/02/18 8.8 6.4 EASI  25  
16 E018015 44/F 4yrs 40 10/04/18 3.2 3.2 EASI 0 
17 J74566 54/M 3yrs 40 22/12/18 5.4 4.8 EASI 25 
18 0566 34/M 5yrs 40 12/4/18 9.6 9.6 EASI 0 
19 0775 50/M 4yrs 40 14/6/18 14.4 9.6 EASI 50 
20 0622 49/F 6yrs 40 23/4/18 12 4.8 EASI 50 
 
Statistical analysis for trail drug: 
 
The mean value of  EASI score  for  patients with trial drug are 17.80 and after 
treatment is 5.73. The p-value is less than 0.0001 which is significant. The reduction in the 
Mean was 67.8%. Hence this study reveals Yogam treatment along with trial medicines is to 
be effective in reducing the symptoms of  Karappan.  
Results after treatment for ESAI SCORE: 
Sl. no Op .no 
Age/ 
Sex DOI 
No of 
Days 
Treated 
EASI     Score 
 
GRADE 
BT AT 
1 0561 53/m 5yrs 40 39.3 6.0 EASI 75 
2 0341 59/M 5yr 40 43.6 5.0 EASI 75 
3 K04479 27/F 7yrs 40 20 2.4 EASI 75 
EASI score Mean± Std p -value 
Before treatment 17.80±10.68 p<0.0001 
After  treatment 5.73± 2.59 
4 F92306 45/F 6yrs 40 16.0 4.0 EASI 75 
5 K18519 33/M 2yrs 40 32.0 4.8 EASI75 
6 H93183 34/m 6yrs 40 24.0 3.6 EASI 75  
7 J27416 38/F 1yrs 40 8.4 0.8 EASI 75 
8 J11986 32/F    5yrs 40 36 12.8 EASI 75 
9 J85942 32/F 3yr 40 24 4.8 EASI 75 
10 J81340 30/F 4yrs 40 7.2 3.2 EASI 50 
11 G29270 54/F 5yrs 40 9.6 8.4 EASI 25 
12 G14967 29/F 10yr 40 9.6 2.4 EASI 50 
13 J88835 52/F 15yrs 40 14 6 EASI 50 
14 J61604 58/F 6yrs 40 28.8 3.2 EASI 75 
15 J86790 57/M 1yrs 40 9.6 1.6 EASI  50  
16 F87188 53/M 4yrs 40 16 4 EASI 75 
17 J71057 37/M 3yrs 40 41.4 14.6 EASI 75 
18 I53173 42/M 5yrs 40 33 9.9 EASI 75 
19 J51869 44/F 4yrs 40 16 2.4 EASI 75 
20 J48553 
31/M 6yrs 40 16.0 8.0 EASI 50 
21 I65375 27/M     1yrs 40 7.2 7.2 EASI 0 
22 J12564 52/F 8yrs 40 8.0 8.0 EASI 0 
23 J86723 47/M 7yrs 40 3.6 3.6 EASI 0 
24 K06028 40/M 2yrs 40 19.2 6.4 EASI 50 
25 J83153 29/M 6yr 40 16 2.4 EASI 75 
26 G92688 33/M 1yrs 40 9.6 3.6 EASI 50 
27 K16575 49/F 2yrs 40 22 6.4 EASI 75 
28 J70192 48/M 4yr 40 28.4 11.8 EASI 50 
29 I59680 44/M 6yrs 40 8 6.4 EASI 25 
30 J64132 
28/M 6yrs 40 
10.8   3.6 
EASI 50 
  31 J83804 37/F 10yrs 40 18 2.4 EASI 75 
32 I38346 45/F 2yr 40 22   4.8 EASI 75 
33 J86172 34/F 4yrs 40 24 6.4 EASI 75 
34 J97100 33/M 8yrs 40 17.6 3.2 EASI 75 
35 F77246 28/M 1yrs 40 8.8 6.4 EASI  25  
36 E018015 44/F 4yrs 40 3.2 3.2 EASI 0 
37 J74566 54/M 3yrs 40 5.4 4.8 EASI 25 
38 0566 34/M 5yrs 40 9.6 9.6 EASI 0 
39 0775 50/M 4yrs 40 14.4 9.6 EASI 50 
40 0622 49/F 6yrs 40 12 4.8 EASI 50 
RESULTS for after treatment( EASI score): 
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Axis Title 
Chart Title 
1 EASI 0 5
2 EASI 25 4
3 EASI 50 11
4 EASI 75  20
5 EASI 100 -
Sl. No Results No of Cases 
Percentage 
1 EASI 75 20 
50% 
2 EASI 50 11 
27.5% 
3 EASI 25 4 
10% 
4 EASI 0 5 
           12.5% 
EASI 0  - No  improvement 
EASI 25 - 25% Mild improvement 
EASI 50- 50% Moderate improvement 
EASI 75- 75% Good improvement 
 EASI 100- 100%Reduction in the score before and after treatment 
Observation: 
                 12.5% of them had no reduction  or minimal reduction in the score, 10% of them 
had 25% of reduction  in the score after treatment, 27,5% of them had 50% of reduction  in 
the score after treatment, 50% of them had 75% of reduction  in the score after treatment 
which indicates the good improvement after treatment.   
 
Statistical analysis for  EASI SCORE:  
 
 
 
The mean value of  EASI score  for 40  patients are 22.22 and after treatment is 5.39. 
The p-value is less than 0.0001 which is significant. The reduction in the Mean was 95%. 
Hence this study reveals Yogam treatment along with trial medicines is to be effective in 
reducing the symptoms of  Karappan. 
 
 
 
 
 
 
 
 
 
EASI score Mean± Std p –value 
Before treatment 22.22±11.89 p<0.0001 
After  treatment 5.39± 3.67 
Photograph 
Before treatment 
                                       
 
 
AFTER TREATMENT: 
 
 
                                
 
  
BEFORE TREATMENT: 
 
 
After treatment 
 
Before treatment: 
 
 
After treatment: 
 
 
                        DISCUSSION 
The main aim of the trial was to study the therapeutic effect of the drug to reduce the 
symptoms of Karappan such as itching, oozing etc. The clinical features of Karappan can be 
correlated to eczema in modern science. Eczema is a non - contagious chronic skin disease 
which is characterized by erythema, scaling, oedema, oozing and vesiculation.   
The drugs which is mentioned in Siddha literature for the management of Karappan 
were selected and the study is conducted after the proposal was screened by the Screening 
committee of National Institute of Siddha and the trial was also approved by the Institutional 
Ethical Committee (IEC). The trial was registered in Clinical trial registry of India. 
The trial drugs were prepared by the Author in the Gunapadam practical laboratory of  
National Institute of Siddha, after getting proper authentication of raw drugs from the 
Medicinal botany department at NIS, Chennai 47. The trial drug was prepared by the standard 
operating procedure as mentioned in the protocol. 
The Biochemical qualitative and quantitative analysis of drugs were performed in 
biochemistry lab of NIS, chennai. The safety of the trial drug usage through  biochemical 
analysis were also ensured during the study. It revealed the presence of effective minerals. 
The patients were recruited for the trial based on inclusion and exclusion criteria and 
after getting the consent from the patient. 40 patients were included in this study.  Out of the 
40 cases, 20 patient were treated with trial drug and remaining 20 patient were treated with 
yogam along with trial drug. Separate proforma was maintained for every patient. Daily 
progress chart was also maintained to monitor the clinical signs and symptoms of the disease.  
The treatment was aimed at normalizing the deranged thodams and providing relief 
from symptoms. Before treatment the patients were advised to take Agathiyar kuzhambu - 
130 mg  with sanganguppi juice in early morning for purgation. The patient was advised to 
take rest without  internal  medicine on that day. 
The patients were treated with trial drugs Parangichakkai chooranam(internal) twice a 
day with water for 40 days and  Karappan ennai (external) for 40 days . Patients were 
instructed to take the medicines regularly and advised to follow pathiyam  and to avoid 
exposure to allergic substances if any. Out-Patients were asked to visit the hospital once in 7 
days. For Out-Patients the internal drug was given for 7 days and external medicine was 
given for 7 days and the clinical assessment was done on 1
st
 day, 8
th
 day, 15
th
 day, 22
th
 day , 
29
th
 day, 36
st
 day and 41
th
 . 
After completion of the study, the patients were advised to visit the Out-Patient ward 
of Department of Sirappu Maruthuvam for another 2 months for follow-up. The results 
observed during the study period were discussed by the author below.   
Among the 40 patients included,  
According to the Gender the disease was found to be higher in males (55%) 
compared to females (45%).  
In Age group maximum numbers of patients 42.5% were in the age group of 41 to 50, 
27.5% were in the age group of 51 to 60, 20% were in the age 31 to 40 and 10%  were in the 
age of 20 to 30. 
 In my study while seeing  socio-economic status  of the patients the disease was 
found to be higher in the  Low income group 62.5%.  lower in the Middle income group 
25%.moderate in the high income group12.5%. Increased incident is present in low income 
group. 
In Occupational  distribution, Among 40 patients 27.5% cases were home makers, 
10%  were at building work as it may be caused by contact with cement, paint, varnish etc, 
12.5% patients were in business , 7.5% of them were coolie, security, powerplant employee, 
5% were house keeping, mechanic, driver, teacher each and  2.5% of them were leather 
factory employee, bank employee, hair stylist, IT proffessional each. According to 
occupational distribution, the chemical handling person and home maker were mostly 
affected. 
In Diet  Non vegetarian (90%) is very higher than the vegetarian (10%). According to 
this, Non-vegetarian were involved. 
Regarding Family history Among 40 patients , 92.5% of the patients showed no 
family history, 7.5% showed positive family history. According to this family history were 
low. 
Regarding  Thinai 90% of the patients were from Neithal(Coastal Area), 7.5% were 
from Kurinji(Hill area) and the remaining 2.5% are from Marutham (Fertile Land). Vatha 
diseases are predominant in neithal thinai. As per the text   skin 
diseases are predominant in neithal thinai, which was seen in this study also. According to 
siddha aspect, Neithal thinai persons were mostly involved. 
l 
 
 In  Paruva Kaalam among the 40 patients admitted for this study, the highest 
number of patients(77.5%) reported in  Munpani Kaalam, 20% are reported in Pinpani 
Kaalam and 2.5% are reported in kootthir kaalam. According to climate variation highest 
incidence is involved in Munpani Kaalam.           
 In Gunam 20% of  cases had Raso gunam 100%. 
 In Yaakai Ilakkanam Out of  40 patients  17.5%  of  them were vatha udal 12.5% 
were pitha udal and  70% had Thontha Udal. 
While seeing  the Naadi, Vatha pitha naadi was found in 62.5% cases, Pitha vatha 
naadi was found in 37.5% cases.  
             In Vatham viyaanan and samanan was affected in all cases (100%) and devathathan 
was affected in 20% of patients, kirukaran was affected in 10% of patients, Abanan was 
affected in 17.5%  of  patients. 
In Pitham among 40 cases Prasakam was affected in all the cases. Vanna Eri 
(Ranjakam) was affected in 7.5% of patients and Atralangi (Sathakam) was affected in 7.5% 
of patients.  
In Iyam  Santhigam was affected in 7.5% of the patients and in  10% of the patients,  
Kilethagam was found to be affected.  
In En vagai thervukal, Niram and Sparisam were found to be affected in all the 
40cases.  
            In  Neikkuri Vatha neer was found in 7.5% patients, Pitha neer was found in  7.5% 
patients and Kaba neer was  found in 85% patients. 
In Udal thaathukkal  among 40 patients, Saaram, Senneer were affected in all the 
cases.  
In Duration of illness the maximum number of patients (32.5%) have the duration of 
illness between 1-5 years, 30% > 1 Year, 22.5% 6-10 yrs, 5% 11-15 yrs, 10% were <15 yrs. 
According to the clinical features  Among 40 patients included in the study 100% 
cases suffered from  itching and hyperpigmentation, 95% of them had oozing and, 10% of 
them had scaling, 17.5% of them had lichenification, 27.5% of them had vesicles, 87.5% of 
them had papules, 40% of them had erythema and 12.5%  of them had hypopigmentation 
In this study, Among 40 patients 60% had the lesion in  both lower limb, 35% had the 
lesion both in upper limb and in lower limb and 7.5% had lesions in Upper limb, Lowerlimb, 
Trunk and face . 
 
Among the  40 patients 20 patients were advised Yogam therapy  along with the trial 
medicines and the remaining others received only the trial medicines. The patients who 
received Yogam therapy along with their medications responded well since the Yogam 
therapy is mainly aimed to reduce the stress, and calms the mind  which plays a vital role in 
better prognosis and reduces the relapse of this disease. 
After treatment Out of 40 cases 12.5% of them (5 patient) had no reduction in the 
score, 10% of(4 patients) had mild improvement, 27.5% of (11 patients) had moderate 
improvement, 50% of (20 patients) had good improvement.  
Patients who were received both treatment had revealed good result and quick 
revealment than the trail medicine taken alone. Based on this, it shows medicine combained 
with yogam therapy is better effective than appropriate to treat the Karappan. 
Laboratory investigation of  blood and urine were done for all 40 cases. There were 
no significant changes in blood and urine parameters before and after treatment.   
In this study no adverse event were absorved during the course of the treatment. After 
the study period all the patients were attend outpatient department of Sirappu Maruthuvam of 
NIS for further follow up of 6 months. 
 
 
 
 
 
 
 
 
       SUMMARY 
 
The disease Karappan was taken for the clinical study with Parangichakkai 
chooranam internal medicine and Karappan ennai external application after scrutinized by 
the Screening committee of National Institute of Siddha.   
The Clinical study was carried out after obtaining proper permission from IEC of  
National Institute of  Siddha (IEC number: NIS/IEC/2016/11-14/14.10.2016) and the trial 
was registered in Clinical trial registry of India with the reference number of 
REF/2018/03/018797.The medicines were prepared after obtaining proper authentication. 
Biochemical analysis of drugs were performed. Hence the study is safely executed on human 
volunteer patients. 
40 patients were treated in  Ayothidoss Pandithar  Hospital of  National Institute of 
Siddha. The patients with Karappan were recruited based on Inclusion and Exclusion criteria 
and detailed study  was  done. Separate proforma was maintained for each patient along with 
daily progress chart  to monitor the prognosis.         
 
 
 
 
 
 
 
 
 
 
 
 
 
CONCLUSION 
          
     The clinical trial proves the efficacy of the trial drugs by reducing the clinical signs 
and symptoms like Itching, Oozing and hyperpigmentation, etc and provides  better cure. The 
study results shows that 12.5% of them (5 patient) had no reduction in the score, 10% of(4 
patients) had mild improvement, 27.5% of (11 patients) had moderate improvement, 50% of 
(20 patients) had good improvement. Thus these results revealed  good relief  from the 
disease  after treatment. 
 The trial medicines were prepared from easily available ingredients and the  
palatability of medicine is better and the dosage is also convenient. 
Yogam treatment along with internal and external medication shows good results in 
patients. When these affected individuals get a better management with this trial drug and 
Yogam, it would be a great benefit for the society. 
In the present study there was no adverse effect were reported in clinical trial. Hence 
the drugs were proven for their safety. The Clinical trial conducted in selected patients was 
satisfactory and encouraging. Further studies may be taken up to establish the efficacy of the 
drug. 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
   
 
 
 
 
 
 
 
 
 
  
 
  
 
 
 
 
  
 
NATIONAL INSTITUTE OF SIDDHA 
AYOTHIDOSS PANDITHAR HOSPITAL 
CHENNAI – 600 047. 
POST -  GRADUATE DEPARTMENT OF SIRAPPU MARUTHUVAM 
A comparative clinical study of Parangisakkai Chooranam (Internal medicine) and 
Karappan Ennai (External medicine) for the treatment of Karappan (Eczema) with and 
without yogam. 
 
 PRINCIPAL INVESTIGATOR Dr.B.R.Dinesh       REG NO: 
FORM l - SCREENING & SELECTION PROFORMA 
 SL.NO                                     OP NO:   
 NAME:     AGE/GENDER:                CONTACT NO: 
INCLUSION CRITERIA 
Age :18-60Yrs                                                                                               M/F Papules   Yes/ No 
Itching Yes/ No Scaling Yes/ No 
Oozing   Yes/ No Vescicles Yes/ No 
Erythema    Yes/ No Hyperpigmentation   Yes/No 
Burning Yes/ No Lichenification Yes/ No 
Willing to give blood 
for investigation  
Yes/ No Willing for admission in IPD for 
40 days or  to attend OPD          
Yes/No 
 
EXCLUSION CRITERIA : H/O 
Hypertension Yes/No Evidence of  any skin disease other than eczema Yes/ No 
Diabetes 
mellitus 
Yes/No Pregnancy and Lactation Yes/No 
Narcotic addicts Yes/No Cardiac ailments Yes/No 
  Varicose eczema Yes/No 
 
ADMITED TO TRIAL  :  YES    NO                          If yes, serial No: 
      OPD                                IPD 
 
Date:        
Station: 
Signature of the Investigator: 
Signature of the Lecturer:                                              Signature of the HOD  
 
 
 
NATIONAL INSTITUTE OF SIDDHA 
AYOTHIDOSS PANDITHAR HOSPITAL 
CHENNAI – 600 047. 
POST -  GRADUATE DEPARTMENT OF SIRAPPU MARUTHUVAM 
A comparative clinical study of Parangisakkai Chooranam (Internal medicine) and Karappan 
Ennai (External medicine) for the treatment of Karappan (Eczema)with and without yogam. 
 [PRINCIPAL INVESTIGATOR ] Dr. B. R. DINESH 
FORM II – CLINICAL RESEARCH FORM 
STUDY  NO                OP / IP NO:    
 NAME:                                                                                 AGE/GENDER:  
ADDRESS :                                                                           CONTACT NO  : 
RELIGION  :  H / M / C / O          
OCCUPATION:                                                                     INCOME: 
MARRITAL STATUS:    MARRIED                                 UNMARRIED         
DATE OF INITIAL ASSESSMENT:                                       
COMPLAINTS & DURATION:                                                                                                                                                                                        
PERSONAL HISTORY: 
         PERSONAL HABITS YES NO IF YES SPECIFY 
DURATION 
AMOUNT/
Qty 
             Smoking     
           Tobacco Chewing     
            Alcohol     
          Narcotic  Drug Addiction     
 
HISTORY OF PREVIOUS ILLNESS AND TREATMENT TAKEN: 
 FAMILY HISTORY: 
 Whether this problem runs in family?         1. Yes                               2.No         
            If yes, mention the relationship of affected person(s) 
1._________________ 
 2._________________ 
DIETARY HABIT:     
                    1.Vegetarian                                              2.Non-vegetarian 
 MENSTURAL HISTORY AND OBSTETRIC HISTORY: 
FORM II a 
GENERAL EXAMINATION:                              Before treatment                    After treatment 
1. Body weight [Kg]    :                      
2. Height [cms]                             :                        
3. Body Temperature [0F]       :   
4. Blood Pressure (mm/Hg)  :      
5. Pulse Rate /min.        : 
6. Heart Rate / min.   : 
7. Respiratory Rate /min.  :   
                                                                                                     Yes            No   
8. Pallor  :   
9. Jaundice  :   
10. Clubbing  : 
11. Cyanosis  : 
12. Pedal Oedema  : 
13. Lymphadenopathy           :  
14. Jugular venous pulsation  :   
 
 VITAL ORGANS EXAMINATION:         Normal          Abnormal 
1.  Heart 
2. Lungs  
3. Brain 
4. Liver 
5. Kidney 
6. Spleen 
7. Stomach   
 
SYSTEMIC EXAMINATION:                    Normal          Abnormal 
1. Cardio-vascular system 
2. Respiratory system         
3. Gastro intestinal system 
4. Central nervous system 
5. Uro-genital system     
6.  Endocrine system        
 
SIDDHA SYSTEM OF EXAMINATION  
1. THEGI (TYPE OF BODY CONSTITUTION): 
1. Vaathaudal                                          3. Kabaudal 
2. Pithaudal                                             4. Thonthaudal 
2. NILAM (LAND WHERE THE PATIENT LIVED MOST):  
 
 
 
 
1. Kurinji                                            3. Paalai 
2. Mullai                                             4. Neithal 
5. Marutham 
3. KAALAM: 
1. Kaarkaalam            4. Pinpanikaalam 
2. Koothirkaalam                                       5. Ilavenilkaalam 
3. Munpanikaalam                                     6. Muthuvenilkaalam 
4. GUNAM: 
1. Sathuvam              2. Rasogunam 
3. Thamogunam 
 
5.PORIPULANGAL(SENSORY ORGANS): 
 1
st
day 8
th
day 15
th
day 22
nd
day 29
th
day 36
th
day  41
st
 day 
Mei (Skin)        
Vaai (Tongue)        
Kan (Eye)        
Mooku (Nose)        
Sevi (Ear)        
 
6.KANMENDRIYAM(MOTOR ORGANS): 
 1
st 
day 8
th
 day 15
th
day 22
nd
 day 29
th
 day 36
th
 day 41
st
 day 
Kai (Upper limb)        
Kaal (Lower limb)        
Vaai (Speech)        
Eruvai 
(Excretory organ) 
       
Karuvai 
(Reproductive 
organs) 
       
 
 
 
 
7.KOSANGAL (SHEATH):          
 1
st 
day 8
th
 day 15
th
day 22
nd
day 29
th
day 36
th
day 41
st
 day 
Annamaya 
Kosam 
       
Pranamaya 
kosam 
       
Manomaya 
kosam 
       
Vignanamaya 
kosam 
       
Aananthamaya 
kosam 
       
 
8.UYIR THATHUKKAL (THREE HUMOURS): 
A. VALI 
 1
st
 day 8
th
day 15
th
 day 22
nd
 day 29
th
 day 36
th 
day 41
st
 day 
Praanan        
Abaanan        
Viyaanan        
Udhaanan        
Samaanan        
Naagan        
Koorman        
Kirukaran        
Devathathan        
Dhananjeyan        
 
 
 
B) AZHAL 
 1
st
 day 8
th
day
 
15
th
 day 22
nd
 day 29
th
 day 36
th
 day 
41
st
 day 
Analakam        
Prasakam  
       
Ranjakam 
       
Aalosakam 
       
Saathakam        
 
 
C. IYAM:             
 1
st
 day 8
th
day 15
th
day 22
nd
day 29
th
day 36
th
day 41
st
 day 
Avalambagam        
Kilethagam        
Pothagam        
Tharpagam
  
       
Santhigam
  
       
 
9.SEVEN UDAL DHATHUS: (7 SOMATIC COMPONENTS)  
 1
st
 day 8
th
day 15
th
day 22
nd
day 29
th
day 36
th 
day 41
st
 day 
Saaram        
Senneer        
Oon        
Kozhuppu        
Enbu        
Moolai        
Sukkilam / 
Suronitham 
       
 
 
ENVAGAI THERVU: [EIGHT TYPES OF EXAMINATION]  
I. NAADI: [PULSE PERCEPTION] 
II. 
SPARISAM: 
1
st
 Day 8
th
 Day 15
th
 Day 22
nd 
day 29
th
 day 36
th
 day 41
st
 day 
       
III. NAA:[TONGUE] 
1
st
 Day 8
th
 Day 15
th
 Day 22
nd 
Day 29
th
 Day 36
th 
Day 41
st
 day 
       
 
1
st
 Day 8
th 
day
 
15
th
day 22
nd
day 29
th
 day 36
th
 day 41
st
 day 
       
VI.NIRAM: [COMPLEXION]   
     1. Vaatham                                              3. Kabam 
     2. Pitham 
 
V.MOZHI: [VOICE] 
1. High Pitched                                                 2. Low Pitched 
      3. Medium Pitched 
VI.VIZHI: [EYES]  
1
st
 Day 8
th
 Day 15
th
 Day 22
th
 Day 29
th
 Day 36
th
 Day 41
st
 day 
       
VII. MALAM: [BOWEL HABITS / STOOLS] 
     Before treatment After treatment 
Niram   
Irugal   
Ilagal   
Others   
 
 
 VIII. MOOTHIRAM [URINE EXAMINATION]   
Neerkkuri Before treatment After treatment 
Niram 
 
  
Manam   
Edai   
Nurai   
Enjal   
 
NEIKURI Before treatment After  treatment 
Aravu (Serpentine fashion)   
Aazhi (Annular/Ringed fashion)   
Muthu (Pearl beaded fashion)   
Kalappu (Mixed fashion)   
Other fashion   
 
  
CLINICAL EXAMINATION:                  
CLINICAL EXAMINATION OF SKIN 
Inspection 
1.Site:     ----------------------------------------------------------------------------------------------------------------------
----------------------------------------------------------------------------------------------------------------------------- -----
---------------------------------------------------------------- 
 
2. Colour:  Normal  Reddish  Black  Greyish 
 
3. Shape:  Irregular  Coin shape Dispersed  
 
4. Itching:  No  Mild  Moderate Severe 
 
5.Oozing:  No  Mild  Moderate Severe 
 
6. Erythema:  No  Mild  Moderate Severe 
 
7. Bleeding:  No  Mild  Moderate Severe 
 
8. Crusting:  No  Mild  Moderate Severe        
 
9. Lichenification: No  Mild  Moderate Severe   
 
 10. Scaling:  No  Mild  Moderate Severe     
 
     YES                      NO 
 
  
14. Ulcération: 
 
 15. Macule:   
 
 16. Papule: 
 
 17. Pustule:  
        
        18. Blister: 
  
19.Vesicle :   
 
 20. Pigmentation:                   Normal                   Hypo                       Hyper  
 
 
 
 
 
 
 
 
 
 
 
 
 
YOGAM ASSESSMENT FORM 
 
STUDY NO:                                           OP/IP NO: 
NAME OF THE ASANAM: 
 Pranayamam  
Day Date Morning Evening Day Date Morning Evening 
Day 1    Day21    
Day2    Day22    
Day3    Day23    
Day4    Day24    
Day5    Day25    
Day6    Day26    
Day7    Day27    
Day8    Day28    
Day9    Day29    
Day10    Day30    
Day11    Day31    
Day12    Day32    
Day13    Day33    
Day14    Day34    
Day15    Day35    
Day 16    Day 36    
Day 17    Day 37    
Day 18    Day 38    
Day 19    Day39    
Day 20     Day 40    
 
 
FORM II C-CLINICAL ASSESSMENT DURING AND AFTER TRIAL 
  
OP/ IP NO:                               STUDY NO: NAME: 
  
AGE/GENDER:  DATE OF RECRUITMENT: 
 1
st
 day After 7 
days 
After 14 
days 
After 
21days 
After 28 
days 
After 35 
days 
After 40 
days 
Itching        
 Oozing         
Erythema         
Papules        
Vesicle        
Scaling        
Pigmentation        
Lichenification        
 
 
Date:          
 
Station: 
 
Signature of the Investigator: 
 
Signature of the Lecturer:                           Signature of the HOD 
                                       
 
      NATIONAL INSTITUTE OF SIDDHA 
AYOTHIDOSSPANDITHARHOSPITAL 
CHENNAI – 600 047. 
POST-GRADUATE DEPARTMENT OF SIRAPPU MARUTHUVAM 
A comparative clinical study of Parangisakkai Chooranam (Internal medicine) and Karappan 
Ennai (External medicine) for the treatment of Karappan (Eczema)with and without yogam. 
       
[PRINCIPAL INVESTIGATOR ] Dr. B. R. DINESH 
 
 
       FORM-III – LABORATORY INVESTIGATIONS PROFORMA 
STUDY NO:                       OP / IP NO:                                     AGE/GENDER:    
BLOOD INVESTIGATIONS 
NORMAL 
VALUES 
BEFORE TMT  
( DATE) 
AFTER TMT 
(DATE) 
Hb( gm/dl) 
M:12-15 
F:11.5-14 
  
T.WBC (cells/cu.mm) 4000-11000   
DIFFERENTIAL 
COUNT (%) 
Polymorphs 40-75   
Lymphocytes 20-40   
Monocytes 2-10   
Eosinophils 1-6   
Basophils 0-1   
T.RBC(million cells/cu.mm) M:4.0-5.5 
  F:3.5-4.5 
  
  ESR(mm/hour) ½ hr. M:1-13 
F:1-20 
  
  1 hr.   
 
  
Blood Investigations Normal Values 
Before TMT 
(DATE) 
After TMT 
(DATE) 
Blood 
glucose 
(mg/dl) 
Fasting    70-110   
PP    80-140   
Random    80-120   
RFT Blood urea    16-50   
(mg/dl) 
Serum creatinine    0.6-1.2   
Serum uric acid M:3-9  F:2.5-7.5   
LFT 
(mg/dl) 
Total bilirubin    0.2-1.2   
Direct bilirubin    0.1-1.2   
Indirect bilirubin    0.2-0.7   
SGOT  (IU/L)    0-40   
SGPT (IU/L)    0-35   
Alkaline 
phosphatase(IU/L) 
   80-290   
Date:  
 
 
 
 
 
 
  
Station: 
Signature of the Investigator: 
 
Signature of the Lecturer:          Signature of the HOD 
 
 
 
 
 
 
 
 
 
 
 
Urine 
investigations 
Before TMT( Date) After TMT ( Date) 
Albumin   
Fasting sugar   
PP sugar   
Deposits 
  
     NATIONAL INSTITUTE OF SIDDHA 
AYOTHIDOSS PANDITHAR HOSPITAL,CHENNAI – 600 047. 
POST- GRADUATE DEPARTMENT OF SIRAPPU MARUTHUVAM 
  A comparative clinical study of Parangisakkai Chooranam (Internal medicine) and 
Karappan Ennai (External medicine) for the treatment of Karappan (Eczema)with and without 
yogam. 
FORM VI: INFORMED CONSENT FORM 
“I have read the foregoing information, or it has been read to me. I have had the 
opportunity to ask questions about it and any questions I have asked have been answered 
to my satisfaction.  
            I   consent voluntarily to participate in this study and understand that I have the 
right to withdraw from the study at any time without affecting my further medical care”. 
"I have received a copy of the information sheet/consent form". 
 
Signature of the participant: 
In case of illiterate participant 
  “I have witnessed the accurate reading of the consent form to the potential 
participant, and the individual has had the opportunity to ask questions. I confirm that the 
individual has given consent freely.”                                                   
 
Date: 
 
Signature of a witness                                                          Left thumb Impression  
                                                                                              of the Participant    
(Selected by the participant bearing no connection with the survey team)   
 
 
Signature of the Investigator 
 
 Signature of the Lecturer                                                    Signature of the HOD 
  
 
FORM V – PATIENT INFORMATION SHEET 
Name of Principal Investigator: Dr.B.R.Dinesh 
Name of the institute: National Institute of Siddha, 
Tambaram Sanatorium, Chennai-47. 
I, Dr.B.R.Dinesh studying M.D (Siddha) at National Institute of Siddha, Tambaram 
Sanatorium is doing a trial on Karappan(Eczema).Eczema is a most common persistent skin 
disease, occurring throughout the world. In this regard, I am in a need to ask you few 
questions. I will maintain confidentiality of your comments and data obtained. There will be 
no risk of disclosing your identity and no physical, psychological or professional risk is 
involved by taking part in this study. Taking part in this study is voluntary. No compensation 
will be paid to you  for  taking  part in this study. 
           You can choose not to take part. You can choose not to answer a specific question. 
There is no specific benefit for you if you take part in the study. However, taking part in the 
study may be of benefit to the community, as it may help us to understand the problem of 
defaulters and potential solutions. 
             If you agree to be a participant in this study, you will be included in the study 
primarily by signing the consent form and then you will be given the internal medicine 
Parangisakkai Chooranam (Internal medicine- 4.2gms BD for 40 days) and Karappan Ennai 
(External medicine), if you wish to stay in the In-Patient ward Yogasanam Treatment will be 
provided to you assuring that you will not be definitely hurt in any course of treatment. 
 The information I am collecting in this study will remain confidential. I will ask you 
few questions through a questionnaire. It will take approximately 20 min of time. Your name 
won’t be mentioned in the lab investigation form instead a code will be used. 
If you wish to find out more about this study before taking part, you can ask me all 
the questions you want or contact Dr.B.R.Dinesh, PG Scholar cum principal investigator of 
this study, National Institute of Siddha, Chennai-47, Phone no: 9597795620,9677220912. 
You can also contact the Member-secretary of Ethics committee, National Institute of Siddha, 
Chennai 600047, Tel No:044-22380789 for rights and participation in the study. 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
NATIONAL INSTITUTE OF SIDDHA 
AYOTHIDOSS PANDITHAR HOSPITAL 
CHENNAI – 600 047. 
POST-GRADUATE DEPARTMENT OF SIRAPPU MARUTHUVAM 
A comparative clinical study of Parangichakkai Chooranam (Internal medicine) and 
Karappan Ennai (external medicine) for the treatment of Karappan (Eczema)with and without 
yogam. 
  
PRINCIPAL INVESTIGATOR  Dr. B. R. DINESH 
 
FORM IV (DRUG COMPLIANCE FORM) 
 
STUDY  NO OP / IP NO:                   NAME:                                            AGE/GENDER:  
DRUG NAME:          Parangichakkai Chooranam 
On 1
st    
 day-Date:  Drugs issued:  (Gms) Drugs returned:    (Gms) 
On 8
th
  day-Date:   Drugs issued:  (Gms) Drugs returned:    (Gms) 
On 15
th
 day-Date:              Drugs issued:  (Gms) Drugs returned:    (Gms) 
On 22
nd
day-Date:  Drugs issued:  (Gms) Drugs returned:    (Gms) 
On 29
th
 day-Date:   Drugs issued:  (Gms) Drugs returned:    (Gms) 
On 36
th
day-Date:              Drugs issued:  (Gms) Drugs returned:    (Gms) 
On 41
st
 day-Date:  Drugs issued:  (Gms) Drugs returned:    (Gms) 
 
 
 
Date Morning Evening Day Date Morning Evening 
Day 1    Day21    
Day2    Day22    
Day3    Day23    
Day4    Day24    
Day5    Day25    
Day6    Day26    
Day7    Day27    
Day 8    Day28    
Day9    Day29    
Day10    Day30    
Day11    Day31    
Day12    Day32    
Day13    Day33    
Day14    Day34    
Day15    Day35    
Day16    Day36    
  
 
 
 
 
 
 
 
 
Date:          
 
Station: 
 
Signature of the Investigator 
 
Signature of the Lecturer                                                                       Signature of the HOD 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Day17    Day37    
Day18    Day38    
Day19    Day39    
Day20    Day40    
1. Patient / consumer identification (please complete or tick boxes below as appropriate) 
        NATIONAL PHARMACOVIGILANCE PROGRAMME FOR  SIDDHA DRUGS 
 
 
Please note:  i.  All consumers / patients and reporters information will remain confidential. 
         ii. It is requested to report all suspected reactions to the concerned, even 
if  it does not have complete data, as soon as possible. 
Peripheral Centre code:     State: 
Name  Father name Patient / Record 
No. Ethnicity  Occupation 
Address  
Village / Town 
Post / Via 
District / State    
Date of Birth / 
Age: 
Sex:     M / F  
Weight : 
Degam: 
 
2. Description of the suspected Adverse Reactions (please complete boxes below) 
Date and time  of 
initial observation 
 Season: 
Description of 
reaction   
 Geographical area: 
 
3. List of all medicines / Formulations including drugs of other systems used by the 
patient during the reporting period: 
Medicine Daily 
dose 
Route of 
administration 
& Vehicle - 
Adjuvant 
Date  Diagnosis for 
which medicine 
taken  
Starting Stopped 
Siddha      
Any other 
system of 
medicines 
     
 
4. Brief details of the Siddha Medicine which seems to be toxic : 
Details Drug – 1  Drug – 2 Drug - 3 
a) Name of the medicine    
b) Manufacturing unit 
and batch No. and date 
   
Reporting Form for Suspected Adverse Reactions to Siddha 
Drugs 
c) Expiry date    
d) Purchased and 
obtained from 
   
e) Composition of the 
formulation / Part of the 
drug used 
   
 
b) Dietary Restrictions if any 
c) Whether the drug is consumed under Institutionally qualified medical supervision or used 
as self medication.  
d) Any other relevant information. 
5. Treatment provided for adverse reaction: 
6. The result  of the adverse reaction / side effect / untoward effects (please complete the 
boxes below) 
Recovered:           Not 
recovered: 
 Unknown: Fatal: If Fatal 
Date of death: 
Severe:   Yes   /   
No. 
Reaction abated after drug stopped or dose reduced: 
Reaction reappeared after re introduction: 
 
 
Was the patient admitted to hospital? 
If yes, give name and address of 
hospital 
 
 
7. Any laboratory investigations done to evaluate other possibilities?  If Yes specify:  
8. Whether the patient is suffering with any chronic disorders? 
Hepatic    Renal    Cardiac    Diabetes    Malnutrition    
Any Others  
9. H/O previous allergies / Drug reactions:  
10. Other illness (please describe): 
11. Identification of the reporter: 
Type (please tick):  Nurse / Doctor / Pharmacist / Health worker / Patient / 
Attendant / Manufacturer /                                                                      
                                Distributor / Supplier / Any others (please specify) 
Name: 
Address: 
Telephone / E – mail if any : 
 
Signature of the reporter:          Date: 
Please send the completed form to:  
                The Director 
                National Institute of Siddha, 
                                                           (Pharmacovigilance Regional Centre For Siddha  
     Medicine), 
                                                           Tambaram Sanatorium, Chennai-600 047. 
                                                            (O) 044-22381314      Fax : 044 – 22381314 
         Website : www.nischennai.org  
         Email: nischennaisiddha@yahoo.co.in   
 
 
 
* * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * ** * * * *  
 
This filled-in ADR report may be sent within one month of observation /occurrence of 
ADR   
 
 
 
 
 
 
Date:                                                                              
Station:  
Signature of the Investigator: 
Signature of the Lecturer:                                                           Signature of the HOD  
                                           
 
 
 
 
 
Who Can Report? 
 Any Health care professionals like Siddha Doctors /  
Nurses / Siddha Pharmacists / Patients etc.  
What to Report?  
 All reactions,  Drug interactions,  
Confidentiality  
 The patient’s identity will be held in strict confidence 
and protected to the fullest extent.  
 Submission of report will be taken up for remedial 
measures only not for legal claim  
Name & address of the RRC-
ASU / PPC-ASU 
        NATIONAL INSTITUTE OF SIDDHA 
AYOTHIDOSS PANDITHAR HOSPITAL 
CHENNAI – 600 047. 
POST-GRADUATE DEPARTMENT OF SIRAPPU MARUTHUVAM 
 
A comparative clinical study of Parangisakkai Chooranam (Internal medicine) and Karappan 
Ennai (External medicine) for the treatment of Karappan (Eczema)with and without yogam. 
 
FORM VIII - DIETARY ADVICE FORM 
 
 
 
 
 BIBLIOGRAPHY 
 
1. Kannusamy parambarai vaithiyam 
2. Sarabaendhira Vaidhya Muraigal 
3. Virana karappan roga sikichai 
4. Sikicha Rathna Deepam 
5. Siddha Maruththuvam Sirappu 
6. Noi Naadal Noi Mudal Naadal Thirattu 
7. Udal Thathuvam 
8. Siddha Maruththuvanga Surukkam 
9. Noi Illa Neri 
10. Siddha Maruththuvam Pothu 
11. Aruvai Maruthuvam 
12. Pathartha Guna Chinthamani 
13. Gunapadam Molligai Vaguppu 
14. Yugi Vaithiya Chinthamani karappan roga nidhanam 
15. Para rasa sekaram kiranthi nidhanam 
16. Pathinen siddhar balavagada thirattu 
17. Athma Ratcha Amirtham 
18. Agathiar rana nool 
19. Agathiar 2000 
20. Thirukkural 
21. T.V. Sambasivam Pillai - Tamil English Dictionary. 
22. Indian Medicinal Plants - Kiritikar and Basu 
23. The Wealth of India 
24. Sarakkugalin Suththi Muraigal 
25. Thotra Kirama Aracheium Siddha Maruthuva Varalarum 
26. Gunapadam Thaathu Vaguppu 
27. Introduction to Siddha Medicine 
28. History of Siddha Medicine Yogam by Dr.R.S.Ramaswamy, --Siddha Maruthuvam 
Special areas-- Published by Tamil Valarchi Kazhagam, Chennai -5. 
29. Yogasana –A comprehensive description about the Yogasana--- Published by Morarji 
Desai National Institute of Yoga 1st Edition (2008) 
30. Pranayama - A comprehensive description about the Pranayama--- Published by 
Morarji Desai National Institute of Yoga 1st Edition (2008) 
31. Yogic Management of Respiratory Disorders--- Published by Morarji Desai National 
Institute of Yoga 1st Edition (2008) 1st Edition (2010) 
32. Chaurasia’s Human Anatomy 
33. Davidson’s Principle and Practice of Medicine 
34. Practice of Dermatology by P.N.Bhel. 
35. Robinson’s pathology. 
36. Basic and Clinical immunology – Mark Peakman 
37. Fundamental Immunology – William E Paul 
38. Ro BI, Dawson TL. The role of sebaceous gland activity and scalp micro¯oral 
metabolism in the etiology of seborrheic dermatitis and dandru€ . J Investigative 
Dermatol SP.2005; 10(3): 194±7. 
39. Gawkrodger DJ. Dermatology, An Illustrated Colour Text. 3rd ed. Edinburgh: 
Churchill Livingstone; 2002. 
 
 
 
 
 
 
 
 
  
 
